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Background: Traumatic Brain Injury (TBI) is a major cause of death and acquired disability. Adult 
studies demonstrate a high prevalence of endocrine dysfunction post-TBI with associated clinical 
morbidity but paediatric data are sparse. Pituitary hormone deficiencies adversely affect growth, 
sexual maturation, energy levels but also cognitive function, particularly memory and concentration. 
Hypotheses: 1) Long-term endocrine dysfunction occurs in children following severe/moderate 
TBI, and possibly mild TBI. 2) There is a relationship between neuro-endocrine dysfunction in TBI 
children and impaired physical, cognitive and psychological functioning and reduced health related 
quality of life (HRQL). 
Aims: To investigate in an established well-characterised prospective cohort of 
severe/moderate/mild TBI adolescents and non-injured controls endocrine status and relationship 
of neuro-endocrine function and neuroimaging changes post-TBI to measures of outcome including 
cognition, psychological status, fatigue and Health-Related Quality of Life (HRQL). 
Methods: TBI participants who had previously participated to KHIS (Kid’s Head Injury Study, Bristol 
2002-2004). Seventy-two participants (age 10-26y, time from TBI 6-11y) completed the study. 
(Group 1 [control group n=17, 14M], Group 2 [mild TBI n=24, 14M] and Group 3 [moderate/severe 
TBI n=31, 20M]). The following assessments were completed (a-c group 3 only, d-e all groups): 
a) Baseline endocrine status b) GH status (Insulin Tolerance Test [ITT] and overnight 12 hour GH 
profile), c) HPA axis status (ITT, overnight 12 hour cortisol profile and salivary cortisol profile), d) 
cognitive, psychological and HRQL assessment, e) pituitary and hippocampus imaging (MRI). 
Results: No auxological differences between groups (height, weight, BMI, body fat percentage). No 
cases of precocious puberty or diabetes insipidus. One female from group 3 had primary 
amenorrhea and GH deficiency. In group 3, GH response to ITT was abnormal in 7/25. Mean 12-
hour GH secretion was low (<1mcg/L) in 4/22 profiles. Peak spontaneous GH secretion was low in 
1/22 profiles. There was no correlation between stimulated and spontaneous GH levels. 
Spontaneous (but not stimulated) GH secretion correlated with IGF1 levels. Cortisol response was 
suboptimal in 2/25 ITT. Peak spontaneous cortisol was under 500 nmol/l in 9/22 profiles, stimulated 
levels were normal in 7 of these. Spontaneous and stimulated cortisol levels correlated strongly. 
Salivary cortisol analysis did not demonstrate differences between groups in regards to diurnal 
rhythm, awakening response or suppression with dexamethasone. Verbal IQ was lower in the 
mod/sev TBI group who also showed difficulties with both externalising (conflict, aggression, rule-
breaking), internalising behaviour (withdrawal, anxiety, depression) and working memory. TBI 
survivors reported high levels of depression (14/46) and fatigue (21/46). HRQL was lower in TBI 
participants mainly because of lower psychosocial scores. Neuroimaging did not demonstrate any 
structural pituitary abnormality. Voxel based morphometry showed reduced grey matter and right 
hippocampus volume in the mod/sev TBI group. 
Conclusions: Childhood TBI is associated with long term endocrine dysfunction. Although all had 
structurally normal pituitary glands, GH status in mod/sev TBI survivors based on ITT was abnormal 
in 28% and in 18% based on overnight GH profile. This did not affect their growth or body 
composition. Fatigue correlated with measures of spontaneous but not stimulated GH. High rates of 
behaviour problems including aggression, rule breaking behaviour but also depression, reduced 
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1 CHAPTER 1 (INTRODUCTION) 
1.1 TBI EPIDEMIOLOGY 
Traumatic brain injury (TBI) - an acute brain injury resulting from mechanical energy 
forces to the head from external sources - is a major cause of hospital admission in 
children and the leading cause of acquired neurological morbidity. Previous studies 
reported that 1 in 100-200 children are admitted to hospital each year following TBI of 
all severities [1] with 80% of them being mild and 20% severe or moderate according 
to the Glasgow Coma Scale [2]. The [GCS] – a neurological scale aiming to offer an 
objective way to record the level of consciousness - has been conventionally used to 
classify brain injury in adults. A modified version [Table 1] has been developed for 
children (Paediatric GCS) [3] to account for the poor verbal performance of even health 
very young children. An admission GCS score of 13-15 signifies mild, 9-12 moderate 
and 8 or below severe TBI. Although mortality rates are higher among patients with 
lower admission GCS TBI (up to 100% with admission GCS of 3), the GCS on its own 
cannot reliably predict the neuropsychological outcome in children with mild [4] or even 
severe TBI in the absence of prolonged hypoxemia [5]. When compared to adults, 
severe TBI in children is associated with lower mortality rates and better functional 
outcome [6]. 
 >5 years <5 years 










Eyes closed (by swelling or bandage) 











No response to pain 
Intubated 
Alert, babbles, usual ability 
Less than usual ability, irritable cry 
Cries to pain 
Moans to pain 
No response to pain 
Intubated 







Obeys commands     Normal spontaneous movements 
Localises to supraorbital pain (>9 months of age) or withdraws to touch 
Withdraws from nailbed pain 
Flexion to supraorbital pain (decorticate) 
Extension to supraorbital pain (decerebrate) 
No response to supraorbital pain (flaccid) 
Table 1 Paediatric Glasgow Coma Scale [3] 
 
TBI in the UK is more prevalent amongst children living in deprived areas with falls 
accounting for more than half of TBI in the under 5 years age group while in the 10-15 
years age group road traffic accidents are the most common cause [7]. TBI as a result 
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of child abuse is more likely to occur in infants [8]. These data collected from a regional 
UK register of all children admitted with TBI still represents a very conservative 
estimate of the true incidence of TBI in childhood and an overestimate of the proportion 
of severe TBI, as most cases of mild TBI are not seen in hospital. Population studies 
estimate that 3.8% of the population experienced at least one hospital admission due 
to TBI by 35 years of age [9]. Almost a third of the general population will have 
sustained a TBI by 25 years of age as reported in recent prospective population 
studies such as the Christchurch Birth Cohort study [10], BIONIC (Brain Injury 
Outcomes New Zealand In the Community) study group in New Zealand [11] and 
Olmsted County (MN, USA) [12]. These large, population-based studies showed the 
incidence of TBI to be 550-800 per 100,000 people per year. In addition, even cases of 
mild TBI that present to hospital emergency departments are likely to be misdiagnosed 
by medical personnel who sensibly focus on ruling out a more severe brain injury that 
may require additional monitoring or intervention. It appears however that once 
moderate/severe brain injury is ruled out (normal CT scan, only brief loss of 
consciousness [LOC] with apparently good recovery) patients with no obvious clinical 
signs of mild TBI by the time they arrive at the ED are more likely not to be diagnosed 
with mild TBI (greatest discrepancy when assessing degree of confusion) [13]. 
For more serious types of injury, requiring admission to paediatric intensive care units, 
the incidence of severe TBI is 5.6 per 100,000 population per year. There was a 
summer peak in admission in children under 10 years with timing of the TBI being 
mostly in the evening [14]. Extrapolation from these data suggest the UK incidence of 
severe/moderate TBI in the paediatric population to be 11.2 per 100,000 per year. 
Causes of childhood TBI in developed countries vary with age. Falls (interestingly the 
major cause of TBI in adults older than 65 years of age), pedestrian road accidents 
and inflicted injuries are the most common causes in infants and children younger than 
14 years of age while motor vehicle accidents, assaults and contact sports injuries 
predominate at older ages. Male children and adolescents have a greater risk of TBI 
due to transport accidents, exposure to mechanical forces or assaults compared to 
girls and women of the same age groups [11]. 
1.2 TBI PATHOPHYSIOLOGY 
In TBI, acceleration–deceleration motions over different planes (sometimes without 
actual impact) apply forces to the brain, which can deform white matter. Deformation of 
white matter results in diffuse axonal injury (DAI) through shearing forces [15]. With 
impact injuries, basal skull fractures may damage the pituitary and/or the 
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hypothalamus directly. Even without skull fracture, tethering of the pituitary to the 
hypothalamus with the pituitary stalk makes it delicate and vulnerable to trauma. Blood 
supply to the anterior pituitary is via the short and long portal vessels. In particular, 
areas containing the somatotropic and gonadotropic cells (usually in the periphery of 
the pituitary) are supplied mainly by the long portal vessels making them more 
vulnerable to ischaemic injury compared to the corticotropic cells which receive their 
blood supply by both long and short portal vessels [16]. This would suggest that the 
somatotropic and gonadotropic cells are more likely to be affected by disruptions in 
pituitary blood supply. Following DAI, oedema (which may cause herniation through 
the diaphragmatic opening and secondary compression [17]), ischaemia and 
excitogenic neurotransmitters may also contribute to the resulting diffuse damage [18]. 
In the chronic TBI phase, loss of pituitary gland volume, perfusion deficits, absence of 
posterior pituitary signal have been described in 80% of patients with hypopituitarism 
and 29% of those without hypopituitarism indicating that pituitary imaging abnormalities 
are more common in TBI patients with hypopituitarism than those without [19]. 
Although several studies suggest that severe TBI is more likely to be associated with 
post-traumatic hypopituitarism (PTHP) [20-22] other studies have not found any 
correlation between PTHP and injury severity as assessed with the GCS [23-25]. 
Interestingly repeated mild TBI may also be implicated in the development of PTHP as 
reported in studies of amateur boxers [26, 27]. 
1.3 TBI AND HYPOPITUITARISM 
The relationship between head trauma and endocrine dysfunction was first described 
in case reports early in the beginning of the last century [Cryan E. 1918] but further 
work on this subject was not published for half a century [28]. Although the wide range 
of pathological changes to the post-TBI brain had been described in detail [17], it was 
only after advances in intensive care and subsequent improved survival of TBI patients 
that more cases of hypopituitarism started being reported [29]. Following these initial 
case reports of PTHP, there has been an increasing recognition that TBI in adults can 
cause endocrine dysfunction as well as neurological, cognitive and psychological 
sequelae [30]. Prospective follow-up studies published over the last decade have now 
conclusively demonstrated hypopituitarism as a cause of endocrine dysfunction 
following TBI in adults and an association with major negative impacts on health. 
Although not as common as anterior pituitary damage, posterior pituitary dysfunction 
has a more dramatic presentation and will prompt further neuroendocrine assessment 
[31]. Benvenga et al (2000) reviewed 367 literature case reports and 15 new cases and 
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concluded that almost half of TBI patients showed evidence of adrenocorticotropic 
hormone (ACTH) or growth hormone (GH) deficiency during the first year after injury 
and delay in diagnosis was a common feature. Kelly et al (2000) described similar 
findings in almost half of 22 head-injured patients with GH and gonadotrophin 
deficiencies being most common [21]. A subsequent study by Lieberman (2001) of 70 
TBI patients from a transitional learning community found that 45% of them had 
subnormal morning cortisol levels, and an abnormal cortisol response to a high-dose 
Synacthen test in 7% [23]. Subsequent follow up studies have reported 20-30% 
prevalence of PTHP in adults following severe/moderate TBI [32-34] with some 
however reporting much higher (up to 80% in the acute post TBI period [35] and 50% 
after a year [36]) and some as low as 5% [37] - a reflection of differences in inclusion 
criteria, time since TBI, use of different diagnostic tests and cut-off values [38]. 
Although multiple hormone deficiencies have been described a year post TBI (range 3-
50%) most participants were deficient in a single axis. Isolated GH deficiency is more 
prevalent (8-38% [39]) which is probably an indication of the susceptibility of 
somatotroph cells to ischaemia or hypoxia. 
Despite however the increasing number of studies in adult PTHP, data regarding 
PTHP in childhood are limited. Aimaretti et al (2005) studied 23 adolescents and young 
adults after TBI and reported PTHP in a third of the patients 3 months post TBI that 
persisted after one year [40]. Ulutabanca et al (2014) in a prospective study of 41 
children (age 7±4 years) with TBI found PTHP in 44% (18/41) of them in the acute post 
TBI phase. 10/41 had low baseline cortisol levels (<15 µg/dL) with inappropriately low 
ACTH, 7/41 were diagnosed with central hypothyroidism (low TSH and fT4) and 1/41 
with hypogonadism. IGF1 was measured in all patients but no GH provocation tests 
were undertaken in the acute phase. When patients were reviewed 12 months post 
TBI, thyroid status was normal in all patients. GH stimulation testing (GHRH-arginine) 
was abnormal in two patients (2/22, 9.1 %) but only one demonstrated slow growth 
post-TBI. One of these patients had also low morning cortisol (<5 µg/dL – a different, 
lower cut-off was used for diagnosing adrenal insufficiency in the chronic vs acute 
phase) with inappropriately low ACTH. This study however was limited by the absence 
of dynamic testing for GH (acute phase) and cortisol deficiency (both in the acute and 
chronic phase). In addition, only half of patients initially recruited were reviewed after 
12 months (22/41) [41]. 
In a cross-sectional study of 36 children with mod/sev TBI who were discharged from a 
Paediatric Intensive Care Unit (all patients has either skull fracture or intracranial 
haemorrhage), no clinical evidence of PTHP was observed 3 years post injury. The 
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mean age at injury was 4 years so it is possible that the low incidence of PTHP in this 
study is a reflection of the different injury mechanism seen in this age group (falls 
rather than high velocity collisions) but also elective use of stimulation tests. In this 
study, stimulation tests were performed only if baseline, blood hormone levels were 
abnormal or when clinical findings suggestive of endocrine dysfunction were present 
[42]. In a prospective study of an older group of 87 children and adolescents (median 
age 6.7, range 0.8-15.2 years) who were hospitalised with severe TBI, PTHP was 
found in 6% a year after TBI applying strict criteria (two stimulation tests with GH 
response <5 mcg/L and IGF-1≤2SDS) [43]. In another prospective study, 23 TBI 
children (age >6 years) underwent two stimulation tests (glucagon and clonidine). 
Almost half (47.8%) showed a suboptimal GH response (using however a 10 mcg/L 
cut-off [44]) three months post TBI which persisted in most of them (8 out of 11) after 1 
year. No endocrine abnormalities were found in a subgroup of younger patients (<6 
years) who were not however assessed with stimulation tests [45]. 
Although older age and male gender appear to increase the risk of PTHP, the risk of 
endocrine dysfunction appears to be much higher if the mechanism of injury is non-
accidental. Auble et al (2014) found endocrine dysfunction in 80% in children (57%, if 
hyperprolactinaemia was excluded) with moderate/severe inflicted TBI. Half of them 
had multiple hormone deficiencies [46]. 
In contrast to the above study, Heather et al (2012) concluded that permanent PTHP is 
rare after both non-accidental (33%) and accidental (67%) TBI in early childhood, in 
one of the largest cross-sectional studies with longitudinal follow-up. Almost two 
hundred survivors of structural TBI were thoroughly assessed 3-9 years post injury. 
The endocrine assessment for GH included two dynamic tests of pituitary function 
(clonidine and arginine) using a cut-off of 5 mcg/L. Eight percent of children 
demonstrated an abnormal GH response but had normal height and IGF-1 (Insulin 
Growth Factor 1) and IGF-BP3 (Insulin Growth Factor Binding Globulin 3). This group 
was followed-up for a period of 6–36 months, and all children showed normal height 
velocity and had normal GH response on repeat testing [47]. 
Khadr et al (2010) in their retrospective exploratory study of 33 TBI survivors (mean 
age 13.4 years) did not find any clinically significant endocrinopathy 1–8 years post 
injury, but minor abnormalities of the pituitary axes were observed [48]. Finally, in two 
of the first paediatric TBI studies Poomthavorn et al. (2008) detected endocrine 
abnormalities in 17% of severe TBI survivors but the study was limited by selection 
bias as only half of the participants had baseline blood tests and only 8/54 stimulation 
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tests [49]. An earlier study by Einaudi et al (2006) found that 10.4% of the 48 patients 
developed thalamo-hypophysial dysfunction 6 months or more after TBI [50]. 
The nature of the relationship between hormone deficiencies and clinical outcome in 
paediatric TBI survivors remains poorly understood. Reviews of the subject confirm the 
pressing need to obtain such data [51] as hormone deficiencies may produce 
additional morbidity in TBI patients who already have a high burden of physical, 
cognitive and psychiatric disability. 
The mismatch between expected and diagnosed PTHP cases has also been a matter 
of debate. The relatively small number of reported cases with PTHP (mainly GH 
deficiency) that are registered in international databases, suggest that PTHP is 
underestimated or under diagnosed [52]. Certainly growth monitoring - the most 
sensitive indicator of pituitary function in children – is not consistently reported in every 
clinical setting, highlighting the need for a co-ordinated approach in any setting 
(hospital or primary care), that is involved in the follow-up of children with TBI [53]. 
Although there is no agreement that the GCS is a reliable predictor of PTHP, it has 
been suggested that all adult patients with moderate to severe TBI should have 
systematic screening of pituitary function to benefit from treatment of PTHP [54]. There 
are not sufficient data however to support similar practice for childhood TBI. The 
studies by Heather et al showing permanent hypopituitarism as being a rare 
consequence after both inflicted (abusive head trauma) and accidental structural TBI in 
early childhood [47] and Salomon-Estebanez showing absence of endocrine sequelae 
in children with TBI related skull fracture or intracranial haemorrhage [42] support the 
above practice. The former study however targeted a group of very young children 
(mean age of 1.7 ± 1.5 yr) and these findings are probably not applicable to 
adolescents, whose physical characteristics and TBI mechanism are similar to those 
seen in adults. In the latter study (which also included prepubertal children), only 
participants who had low IGF1 were reassessed after one year. In all of them IGF1 
levels normalised after a year so no further tests were undertaken. Once again, the 
authors highlight the importance of growth monitoring in children after TBI and suggest 
that “invasive assessments should be reserved for selected cases where there is slow 
growth or other clinical suspicion of hypopituitarism”. 
Assessments of endocrine function can be complex and difficult to interpret. Although 
thyroid, gonadotropin and posterior pituitary function can be reliably assessed with a 
baseline blood test, diagnosis of GH or ACTH deficiency is more problematic. For 
practical reasons dynamic, non-physiological and potentially dangerous tests are still 
being used. Unfortunately, interpretation of these tests and their numerous 
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combinations remains complex. By using the same and sometimes arbitrary diagnostic 
cut-offs in different populations (age, weight, pubertal stage) with different assays, it 
would be reasonable to assume that part of the variability of the reported prevalence of 
PTHP is related to different study methodologies and interpretation of tests. Although 
alternative approaches for diagnosing GHD based on combinations of auxological, 
radiological, biochemical and genetic measures have been proposed [55], stimulation 
tests remain the standard for assessing GH status as GHD is a diagnosis based on 
biochemical evidence of reduced/absent GH secretion. 
1.3.1 Growth hormone 
1.3.1.1 Growth hormone structure 
Growth hormone (GH) is a 191 amino acid polypeptide with a molecular weight of 22-
kDa. In addition to the 22-kDa isoform that constitutes 75-90% of pituitary GH, several 
other molecular isoforms of GH exist (20-, 17-, 5-kDa), the physiological significance of 
which remains mostly unknown [56]. The 20-kDa isoform, which represents 10% of 
circulating GH, is co-secreted with the 22-kDa GH lacking amino acids 32-46. The 
biological activity of both forms is thought to be comparable [57]. Some of these 
isoforms are detected to a variable degree by available GH assays. As a result 
measured levels of GH differ depending on the assay used [58]. The main GH isoform 
and these variants circulate partially bound (up to 50% [59]) to binding proteins (growth 
hormone-binding protein, GHBP), which have a structure identical to the extra-cellular 
domain of the GH receptor [60]. 
1.3.1.2 Growth hormone physiology 
GH is secreted from somatotroph pituitary cells in a pulsatile pattern following 
constantly changing equilibrium between stimulatory (GH-releasing hormone [GHRH] 





Figure 1 Human GH axis – neuromodulators 
 
GHRH is predominantly produced in the arcuate nucleus while SS in the 
paraventricular nucleus [Figure 2]. SS determines the trough levels of GH by inhibiting 
GHRH release. Pulses of GH occur when SS tone is withdrawn – this usually every 3-4 
hours. A variety of neurotransmitters, metabolites (glucose, amino acids), hormones 
(oestrogen, testosterone, insulin) but also GH itself and IGF-1 may exert a positive or 
negative effect when binding to specific hypothalamic receptors and therefore mediate 
GH secretion [63]. Although fasting normally increases GH secretion via inhibition of 
SS release, this effect is not seen in obese patients. This suggests that metabolic 
changes (insulin resistance) rather than hypothalamic mechanisms are responsible for 




Figure 2 Growth hormone related hypothalamic nuclei 
 
The pulsatile pattern of GH secretion has been confirmed in other species from foetal 
life [65]. In humans, GH is secreted in markedly amplified GH-secretory bursts from the 
early neonatal period [66]. In the first day after birth, there is GH hypersecretion with 
increased frequency (every 70 min) and amplitude of GH pulses. Gradually and with 
the development of inhibitory mechanisms (mainly SS release), GH release becomes 
pulsatile. The effect of SS is not only on the pituitary level but also on hypothalamic 
GHRH and insulin release [67]. The net result of high circulating SS is a decrease in 
the mass and frequency of GH secretory events. As with other hormones 
(gonadotrophins), pulsatile GH secretion may be necessary for tissue specific 
responses. 
Although the pulsatile pattern of GH secretion continues throughout childhood and 
adult life, the frequency and amplitude of GH pulses evolves. During puberty there is a 
marked increase in GH secretion. This is due to increased amplitude of GH pulses with 
some notable differences between men and women. In men, GH pulsatility is more 
evident during the night with large pulses and low trough levels while in women there is 
less diurnal variation with higher trough levels and nocturnal pulses of lower amplitude 
[68]. 
Single measurements therefore do not reflect endogenous GH secretion and will 
produce an uninterpretable result in virtually all cases except during the early neonatal 
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period when SS tone is not yet established. Various protocols have therefore been 
developed to access GH secretion in a more predictable and controlled way. 
1.3.1.3 Assessing GH status 
Testing methods used for diagnosing impaired GH secretion include pharmacological 
(stimulated GH secretion) and physiological (measurement of spontaneous GH 
secretion over a period of time – usually 12 or 24 hours). There is considerable 
variability in GH status even when repeating the same test in the same individual, 
which suggests that the variability is test- rather than patient-related [69]. 
1.3.1.3.1 Pharmacologic tests for GH secretion 
A number of different stimulation tests using various stimuli have been used for 
assessing GH status. In decreasing frequency based on a pharmaco-epidemiological 
survey these include pharmacological agents like insulin, arginine, clonidine, L-dopa, 
glucagon, GHRH, ornithine [70]. 
Historically insulin was used as an indicator of growth hormone status based on the 
ability to recover from the induced hypoglycaemia. Roth et al [71] was the first to 
demonstrate the GH response to insulin-induced hypoglycaemia (Insulin Tolerance 
Test [ITT]) in 6 healthy adults. By sampling every 30 min for several hours, he was 
able to demonstrate a rise in GH levels 30 min after hypoglycaemia in all except one 
participant, to levels usually found in “random plasma samples from acromegalic 
subjects”. This study became the basis of using insulin-induced hypoglycaemia as a 
direct test of pituitary somatotropic function. Further studies [72] confirmed this 
observation in both healthy volunteers and patients with hypothalamic or pituitary 
dysfunction. The author also described – in his healthy, adult volunteer group - 
markedly variable, individual GH levels but also poor reproducibility of the GH 
response in comparison to cortisol, free fatty acid and plasma glucose. 
The test is regarded as safe when done by appropriately trained staff, in a safe 
environment and in patients without a history of seizures or heart disease. An audit of 
over 500 tests over a 10 year period (1989–99) from a tertiary paediatric centre in the 
UK, reported no serious adverse events [73]. An earlier serious incident associated 
with the ITT involved the administration of inappropriately large quantities of 
intravenous dextrose to correct the insulin induced hypoglycaemia [74]. 




 The test is sensitive to weight and therefore not as reliable in diagnosing GH 
deficiency in obese children [75]. 
 As sex steroids enhance GH secretion during puberty, the practise of “priming” 
children of almost normal pubertal age with sex steroids for the purpose of the test, 
may have a similar effect. 
 Finally, age appropriate cut-offs should be used. In adults having an ITT, a GH cut-
off of 3mcg/L has been accepted [76] to diagnose GHD, while in children 7-10 
mcg/L is being used in most centres. During the transition phase, a cut-off of 5 
mcg/L achieved the best sensitivity and specificity [77]. 
1.3.1.3.2 Physiologic tests for GH secretion 
The first detailed studies in physiological GH secretion patterns in healthy adult 
participants, showed increased GH secretion with the onset of sleep. Sleep consists of 
5 stages (1, 2, 3, 4 and REM [Rapid Eye Movement]) and sleep cycle is defined as the 
period of time it takes for an individual to progress through all stages before returning 
to stage 1. A typical full cycle last about 100 minutes [78]. GH is released mainly during 
sleep stages 3 or 4 and is suppressed during periods of awakeness [79, 80]. The 
described GH secretion pattern is relatively uniform, starting 1-2 hours after sleep 
onset. The observed peak GH levels are reported to be comparable to those seen 
during stimulation tests. Interestingly this pattern of GH secretion is related only to 
sleep onset without any obvious circadian rhythm [81] [Figure 3]. 
 
Figure 3 Growth hormone secretion in relation to sleep stages (Takahashi et al) 
A similar pattern has been described in children where GH secretion during the day 
was lower than during the night period with the difference being more marked in short 
children [82] and some authors concluding that by using a single sample 1 hour after 
the onset of deep sleep, GHD could be precluded in as many as 70% of children [83]. 
In another study with similar design of short, prepubertal children without GHD (i.e. 
normal GH response to one or more pharmacological tests), at least one GH secretory 
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peak was observed in all children during sleep which was above the cut-off being used 
in that centre for pharmacological tests [84]. 
Early studies in children comparing peak GH response to ITT with peak GH 
concentration during the first cycle of stage 4 sleep, showed that results were 
discordant in less than 15% of children [85]. The authors suggest that the sensitivity of 
sleep sampling under EEG monitoring could be improved with information obtained 
from a complete 12 hour overnight profile as the maximum GH peak is not necessarily 
associated with the first cycle of stage 4 sleep. Growth velocity was also found to 
correlate with the mean GH level over 12 hours (or area under the curve), number of 
GH concentration peaks ≥ 5mcg/L and peak GH concentration 1 hour from sleep 
onset. Comparisons between normally growing and poorly growing children have 
shown that the difference in GH secretion is due to lower amplitude of same number of 
GH peaks rather than reduced number of GH secretory episodes [86]. 
When compared to GH stimulation tests, mean overnight GH secretion was found to 
have 100% specificity but variable sensitivity (54-95%) [87, 88]. Studies of 
spontaneous GH hormone secretion in normal children have shown that GH secretion 
depends on pubertal stage, sex, BMI and bone age and interpretation of data should 
therefore be done in relation to appropriate normative data which adds to the 
complexity of interpretation. These differences however become less significant at later 
states of puberty and mean overnight GH levels above 1mcg/L (using polyclonal RIA, 
Hazleton Biotechnologies, Vienna, VA) were seen in all healthy participants 




Figure 4 Spontaneous growth hormone during puberty in normal girls and boys (Reproduced from Rose, 
S.R., et al. J Clin Endocrinol Metab, 1991. 73(2): p. 428-35) 
 
Other researchers have found a strong correlation between mean 12-hour nocturnal 
GH concentration and growth velocity in all slowly growing children (height velocity less 
than 3rd percentile for bone age) having a mean nocturnal GH concentration less than 
4 mcg/L [90]. This led to the measurement of endogenous GH secretion in short 
children who were not GH deficient by conventional criteria (i.e. abnormal GH 
response to stimulation test). Results from these studies identified a subgroup of 
children where sleep-associated GH release was reduced and who benefited from GH 
therapy [91]. In another study spontaneous maximum GH concentration during night-
time sampling in children was a better predictor for the response to GH treatment than 
peak GH concentration following provocation testing [92]. 
In a more recent study [93] comparing nocturnal GH secretion in pre-pubertal and post-
pubertal lean and obese study participants using a modern, automated 
chemiluminescence assay (Nichols Luma Tag hGH), mean overnight GH concentration 
was 5.7±0.3 and 3.6±0.5 mcg/L for the lean and overweight pubertal participants 
respectively. The reduction in GH secretion in overweight participants was secondary 
to reduced GH burst mass (metric from deconvolution analysis of GH profiles) and half-
life but not because of changes in number of secretory events. The former is controlled 
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by GHRH secretion while the latter by SS and the same pattern has been 
demonstrated in studies of obese adults [94]. 
Although the pattern of growth hormone secretion in pre-pubertal and post-pubertal 
boys and girls is similar, during puberty sex-specific increases in GH secretion rate 
occur (sexual dimorphism). These appear at an earlier pubertal stage and are more 
pronounced in girls than in boys [95]. Not only the secretion rate but also the 
orderliness (as measured by Approximate Entropy [96]) of GH release is controlled by 
sex steroid hormones with the pattern of GH release becoming more irregular in 
pubertal boys as sex steroid concentrations rise [97]. The increased GH secretion 
rates during puberty are a result of a 2-3 fold increase in the mean serum GH 
concentration peak amplitude. The frequency of detected GH pulses using discrete 
peak detection methodologies remains unchanged [98]. The same pattern has also 
been described in boys with constitutional delay of puberty treated with testosterone. In 
these boys, treatment with testosterone increased the amplitude of GH-secretory 
peaks without changing pulse frequency, or pulse duration [99, 100]. In normal girls, 
pubertal GH elevations are proportionate to the rise in serum oestradiol levels and 
reach a peak 2- to 3- fold increase compared to pre-puberty at menarche [101]. 
Interestingly, the enhanced GH secretion of puberty gradually declines to below 
prepubertal levels, despite continuing adult sex-steroid hormone concentrations [100] 
Figure 5. 
 
Figure 5 Daily GH secretion rates by age (Adapted from A. Iranmanesh et al. [102]) 
 
Spontaneous GH secretion rate estimates seem to be stable and reproducible [103, 
104] and according to some researchers even more consistently reproducible 
compared to pharmacological tests [88]. Others however question the advantage of 
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spontaneous GH secretion compared to stimulation tests in prepubertal children, as 
measurements of spontaneous GH secretion were considerably less sensitive 
(sensitivity 57%; specificity 100%; predictive value of a low mean nocturnal GH level 
100%; predictive value of a normal mean nocturnal GH level 76% when using a mean 
GH cut-off level of 1mcg/L) [87, 105]. These results did not change significantly even 
when the cut-off level for diagnosing GHD with the use of a stimulation test was 
lowered from 7 mcg/L to 5 mcg/L. According to the same authors, testing of 
spontaneous GH secretion did not identify any GH deficient children that had not been 
already identified by a stimulation test. They did however suggest that overnight GH 
studies could be useful in selected clinical settings such as cranial irradiation in 
oncology patients or other central nervous system disorders which may include 
inflammatory conditions and possibly TBI [106]. 
As stimulation tests are less labour intensive, require a smaller number of samples and 
considered to be equally reproducible by some authors they were adopted early [71] 
and became the standard method of estimating GH secretion despite not being able to 
provide an explanation of the slow growth in children with “normal” GH response to 
stimulation test. This condition, referred to as GH “neurosecretory dysfunction” 
highlighted the importance of assessment of spontaneous GH secretion especially as it 
was shown to correlate closely with growth rate [107-109] and subsequent clinical 
course in comparison to stimulation tests [110]. 
In line with pharmacologic tests for GH secretion, it is reasonable to accept that using a 
universal cut-off value to define normality when assessing spontaneous GH secretion 
is misleading, as GH secretion is a continuous variable (notwithstanding the inherent 
problems associated with the performance of GH assays and how the test is 
performed) [111, 112]. 
To complicate interpretation of GH secretion normality, measured plasma GH levels do 
not reflect actual GH secretion as the plasma concentration at any time point is the 
result of GH secretion from somatotroph cells in the pituitary, distribution of GH in 
various compartments, binding, metabolism and excretion/elimination. The exact timing 
of GHRH release will therefore be inevitably blurred by the secretory and post-
secretory events. 
Advances in computer technology made it possible to undertake complex analyses – 
initially separating pulsatile signal from noise and then deconvolution analyses - and 
obtain reliable estimates of the pulsatile pattern of endocrine systems including GH 
secretion [113]. This still requires sampling at optimal intervals, which are mainly 
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determined by the half-life of GH, for which the elimination mechanisms are still largely 
unidentified. Fortunately, endogenous GH hormone disappearance rates as 
determined by deconvolution, agree well with those reported after exogenous GH 
hormone injections but also from GH kinetic studies where GH and somatostatin were 
given in combination (somatostatin given in order to supress endogenous GH 
secretion). The half-life of GH is estimated to be between 9-15 min with a mono-
exponential disappearance curve. This would suggest that 10-15 min GH sampling 
intervals are optimal in order to determine the pattern of secretion when using discrete 
sample methodology [114, 115]. With integrated sampling, in which blood is withdrawn 
continuously over time periods and assayed in defined time segments, 20 min 
subsampling frequency would seem to capture the essential major details of profiles 
[116]. More intensive 5-min or even 1-min sampling has been found to detect a higher 
number of peaks (all additional peaks however were detected within the GH major 
secretory peaks) when using an objective, statistically based pulse detection algorithm 
(Cluster). This suggests that major secretory episodes of GH release (detected fairly 
consistently with 10-30 min sampling) incorporate high-frequency GH secretory activity 
[117]. If however the focus is the secretion rate alone, longer sample intervals (up to 
30-min) are sufficient [Figure 6]. 
 
Figure 6 Simulated GH profile with different sampling intervals (adapted from Diagnostics of Endocrine 
function in children and adolescents 4th Edition) 
 
In early attempts to characterise GH secretion patterns, samples would be obtained 
serially over a period of hours or days, assayed and a “scorer” would identify peaks 
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(arbitrarily defined as a deviation from baseline of at least 20% [118]) by inspection and 
count them for analysis. This manual and highly subjective method of identifying GH 
peaks complicated communication among different researchers and was subject to 
bias at many different levels. 
Time series analysis was one of the first methods used; the principle behind time 
series being that any complex waveform can be expressed as a combination of sine 
and cosine waves with various frequencies. Following time series analysis, Fourier 
transformation can be applied to reveal dominant features [119]. Such methods, 
however, cannot deal with irregular cycles, which is the typical pattern seen with most 
biological systems. 
Pulse detection algorithms (Pulsar [120] and Cluster [121] being the most widely used) 
were subsequently developed to characterise GH secretion. Pulsar would identify 
secretory episodes by comparing the height from a baseline while taking into account 
the assay standard deviation. The Cluster program would define a pulse as a 
“statistically significant increase in a cluster of hormone values followed by a significant 
decrease in a second cluster of values” by using a sliding, grouped t-test. This method 
is limited in that it cannot adjust for varying trough hormone concentration, pulse 
amplitude and duration. Both Cluster and Pulsar algorithms operate at a similarly peak 
detection efficacy with 20-min GH sampling [120]. 
Development of sensitive GH assays that are able to detect low concentrations of GH 
and newer computer algorithms that are able to define parameters of GH secretion by 
an automated, statistically based approach, has enabled representation of hormone 
secretory episodes by a Gaussian distribution of brief molecular secretory episodes 
around a particular time point. 
Deconvolution methods take pulse detection algorithms a step further, as they are able 
to expose underlying GH secretion rates by taking away the influence of GH 
elimination on the measured plasma concentration [122, 123] [Figure 7]. They can 
therefore present information about regulation of secretory activity and enable detailed 




Figure 7 Multiple-parameter deconvolution model 
 
1.3.2 Cortisol 
1.3.2.1 Cortisol physiology 
The hypothalamus–pituitary–adrenal (HPA) axis is a major endocrine system, which 
plays a crucial role in maintaining homeostasis and adaptability to physical and 
environmental challenges [125]. Cortisol, the final product of the HPA axis, binds to 
glucocorticoid receptors that are abundant in almost every bodily tissue and facilitates 
metabolic processes related to glucose utilization and delivery to the brain and 
muscles in addition to maintaining blood pressure and hence peripheral blood 
perfusion. 
Corticotrophin-releasing-hormone (CRH) is synthesized at the level of the 
paraventricular nucleus (PVN). The PVN receives input from the suprachiasmatic 
nucleus (SCN) in the hypothalamus which synchronises the body’s circadian rhythms 
[126]. Via the portal circulation, CRH reaches the anterior pituitary and stimulates the 
secretion of adrenocorticotropic hormone (ACTH) which in turn reaches the adrenal 
cortex and stimulates the synthesis and secretion of glucocorticoids [127]. 
The HPA axis has a distinct diurnal rhythm with short secretory episodes of high 
amplitude starting in the second half of the night with peak cortisol levels in the early 
morning [128]. An additional brisk increase in cortisol levels, embedded in this 
circadian pattern but relatively distinct from components of circadian cortisol secretion, 
is seen 20-30 minutes after awakening (cortisol awakening response [CAR]) [129]. 
Cortisol levels during this brief period rise by almost two fold and remain elevated for at 
least 60 minutes [130]. CAR shows high intra-individual stability (r= .45 - .70) even 
when measured at monthly intervals and in different age groups [131]. Thereafter, 
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cortisol levels gradually decline throughout the day with lowest levels seen around 
midnight [132]. 
The CAR is therefore considered a useful indicator of the integrity of the HPA axis. The 
cortisol increase can be supressed after intake of a low-dose dexamethasone the night 
before suggesting that CAR is mainly driven by hormonal release from the pituitary 
[133] influenced by orientation in time [134]. This is supported by the increased post-
awakening cortisol production seen by using a dawn simulator producing increasing 
light levels before awakening [135]. 
Although stress and depression can result in an enhanced CAR the results from 
various studies are mixed [136]. It is possible that differences in sleep and gender 
could account for these differences as although depressive symptoms are associated 
with an elevated CAR in females, in males the result is a blunted CAR [137]. 
Another important factor that needs to be taken into account whenever interpreting 
CAR data is the temporal accuracy of saliva sampling. Although the first sample should 
be taken immediately after awakening, studies that were able to verify awakening and 
sampling times found delays in sample collection by >30 min on 14% of sampling days 




Figure 8 Illustration of the impact of sampling in CAR estimation.S1 denotes the first sample on 
awakening. Differences in the estimated Area under the Curve (AUC) can be seen with delays of 20 and 




Although the HPA axis is mainly regulated at the level of the PVN with input from the 
SCN, other brain regions including the hippocampus have been found to play a role in 
modifying HPA axis activity. Reduced hippocampal volume is associated with 
impairment of hippocampus-dependent cognitive processes and persistently elevated 
cortisol levels while larger hippocampal volume is associated with a greater CAR [139]. 
Taken together, these results suggest a central role of the hippocampus in regulation 
of the CAR. 
1.3.3 Impact of post traumatic hypopituitarism (PTHP) 
In addition to its growth promoting effects, GH plays an important role in maintaining a 
healthy metabolic profile, body composition with increases in lean body mass and bone 
density but also memory, cognition, mood and HRQL [140, 141]. Treatment with GH in 
GH-deficient children has been shown to improve cognition, especially performance IQ 
and processing speed [142]. 
GHD is associated with increased risk of developing adverse cardiovascular and 
cerebrovascular events - a combined result of various factors including reduced left 
ventricular mass, endothelial dysfunction and increased visceral fat [143]. Treatment 
with GH has a beneficial effect possibly by improving endothelial function and reducing 
arterial stiffness [144]. The beneficial effect of hormone replacement in patients with 
hypopituitarism is well established [145]. 
Hypogonadism is associated with infertility, adverse changes in body composition/bone 
mineralisation [146] and increased risk for cardiovascular and cerebrovascular events. 
Depending upon the age and gender of the TBI individual, the symptoms of 
hypogonadism can vary. Women can exhibit amenorrhea, decreased libido, fertility and 
reduction in bone density. Men can present with fatigue, reduced lean/muscle mass, 
loss of secondary sexually characteristics and decreased libido and fertility. 
Gonadotrophin deficiency has been found to be a significant independent factor for 
development of cerebrovascular disease, essentially increasing mortality two fold 
compared to the general population [147]. It is also associated with impairment of 
some aspects of cognitive function, particularly verbal fluency [148]. 
Glucocorticoid deficiency can cause lethargy, weakness, fatigue and cognitive 
dysfunction [149]. With secondary hormone deficiencies as seen with TBI, most 
mineralocorticoid secretion remains intact. Corticotropin deficiency is therefore less 
evident than primary adrenal deficiency. 
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Hypothyroidism causes fatigue, poor concentration and memory problems which can 
be ameliorated by treatment [150, 151], but again the clinical phenotype is less severe 
than that seen in primary hypothyroidism.  
1.3.3.1 Fatigue, HRQL, cognitive function and PTHP 
Persisting mental and physical fatigue has been reported in up to 80% of traumatic 
brain injury patients even at 5 years post TBI [152, 153] . This is much higher when 
compared to the lifetime prevalence of fatigue in the general population (24%) [154]. In 
the first year post-TBI, fatigue levels are more likely to improve, remain stable or 
increase following mild, moderate and severe TBI respectively and correlate strongly 
with depression, insomnia, and cognitive difficulties [155]. Various mechanisms have 
been proposed to explain fatigue in patients with TBI including excess mental effort to 
overcome memory, problem solving and attention impairment, disordered sleep and 
hypopituitarism [156]. Although fatigue levels between GHD and non-GHD TBI 
survivors (irrespective of TBI severity) have been reported to be comparable [157, 
158], studies of GHD patients from non-TBI causes indicate an association between 
GH status and fatigue. The discrepancy could be related to the small number of 
patients recruited in the formal studies as it is well described that GHD is associated by 
a described reduction in cardiorespiratory endurance which can present as physical 
fatigue [159, 160]. It would be reasonable to assume that treatment with GH would 
reduce fatigue in these patients. This has been confirmed with double blind, placebo 
controlled studies that have demonstrated an overall improvement in energy levels with 
GH replacement therapy in GHD [161-163]. 
The potential benefit to patients of correcting post-TBI endocrine deficits is further 
highlighted by evidence that adults with GHD following TBI, show a marked 
improvement in HRQL (including social and psychological wellbeing) but also in 
cognitive function, organisational skills, co-ordination and fine motor dexterity after 
treatment with GH [164]. Analysis of the German International Metabolic database 
(KIMS) in 2006 identified 84 TBI patients on GH treatment (54 adult-onset and 24 
childhood-onset). When compared to a matched group of GHD patients due to non-
functioning pituitary adenoma, they showed a similar benefit from GH replacement in 
terms of improved HRQL [172]. 
Although impaired cognitive function is a well-recognised complication of TBI, the 
relationship between TBI-related hypopituitarism and cognitive dysfunction is not clear. 
Children with congenital hypopituitarism have an intellectual ability that is in the low-
average range compared to the population norm but not significantly different when 
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compared to their siblings except for performance IQ (reflection of reduced ability to 
perform tasks requiring perceptual organisational skills) [165]. These children are 
susceptible to hypoglycaemia and other hormone deficiencies early in life that can 
affect the developing brain and are recognised causes of neurocognitive dysfunction 
[166] without forgetting that children with congenital hypopituitarism are also likely to 
have an abnormally developed brain to start with. Furthermore, intelligence in children 
with GH insensitivity due to abnormal GH receptor is not different compared to controls 
indicating that GH-induced IGF-1 production is not required for normal brain growth or 
for postnatal intellectual development [167]. 
Considering that GH and IGF-1 receptors are found in the thalamus, hypothalamus, 
hippocampus and parahippocampal areas it is still possible that GH exerts a 
neurotrophic effect in childhood but also during adulthood [168]. Although some of GH 
actions are mediated through IGF-1, the expression of GH receptors in the brain 
suggests a direct effect on neural cells especially as GH receptor is upregulated 
following brain injury and in response to GH administration [169]. Experimental 
research raises the possibility that at least some of the adverse effects of hormone 
deficiencies following TBI might be related to an impact upon endogenous neuro 
reparative processes [170, 171]. 
1.4 TBI AND QUALITY OF LIFE 
The impact of endocrine dysfunction following TBI is likely to be even more significant 
in children than in adults because of the crucial roles of pituitary hormones in growth, 
puberty and the successful physical and psychological transition from childhood to 
adulthood. TBI children have significantly lower HRQL than non-injured controls 
several years post injury [172] but in contrast to parent report they do not always rate 
their HRQL much differently compared to their peers when assessed a mean of 4 
years post TBI [173]. The reduction in HRQL correlates not only with injury severity but 
also with levels of cognitive and psychological dysfunction. 
Kokshoorn et al (2011) [37] reported differences in HRQL between patients diagnosed 
with and without hypopituitarism at least one year after TBI. From the 112 patients that 
were included in the study (age 19-69 years, time since TBI 4±3 years) six were 
diagnosed with one or more pituitary hormone deficiencies following a single dynamic 
test (3 GHD, 1 GHD and cortisol, 1 cortisol, 1 hypogonadism). As a group, patients 
with PTHP had problems with depression, social isolation, reduced activity and 
reduced general health perception. In another retrospective study of 97 symptomatic 
(presence of psychiatric or neuropsychological deficits like chronic fatigue, impairment 
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of alertness, listlessness) TBI patients, Nourollahi et al [174] found that all patients had 
significantly lower HRQL compared to the standard population. In addition patients with 
PTHP had also worse HRQL compared to patients without PTHP. 
1.5 TBI AND BEHAVIOURAL OUTCOMES 
Behavioural and psychosocial problems following TBI in childhood have not received 
the same attention as the physical and cognitive consequences. As damage to neural 
substrate after TBI can affect neurocognitive skills that mediate behaviour, children 
following TBI are at increased risk of adverse behavioural outcomes. The effects of 
injury severity are not clear [175, 176] for most behavioural outcomes except possibly 
for personality changes that may be noticeable shortly after injury [177]. With modern 
imaging modalities (DTI and fMRI) it is now possible to assess subtle changes in white 
matter integrity. Executive functioning (task planning, inhibition, attention control, 
sustained effort, and mental flexibility) for example relies on frontal–striatal networks 
that are particularly susceptible to diffuse axonal injury [178]. Approximately 20 to 40% 
of young children (5-15 years of age) with TBI show significant executive dysfunction 
within the first year of injury [179]. Frontal and temporal area networks are also 
important for processing emotional information. Acquired brain injuries to these areas 
(e.g. TBI, stroke, meningitis) can predict deficits in processing and recognizing 
emotions, executive function and general cognitive functioning [180, 181]. 
Early studies of children following severe TBI suggested that the risk of experiencing 
TBI is influenced by the child’s pre-accident behaviour, intellectual level, and 
psychosocial circumstances [182, 183]. Other studies have reported a threefold 
increase of new psychiatric disorders compared to children with mild TBI (62% vs 20%) 
or orthopaedic injury controls [182, 184]. These studies however have relied on post-
injury collection of pre-injury data and it is possible that parental perception of the 
child’s past behaviour was influenced by the child’s current behaviour. In addition these 
studies included only children that were hospitalised or seen in emergency 
departments while children with mild TBI are usually seen in primary care [10]. It is 
therefore possible that children with mild TBI presenting at hospital and included in 
these studies of hospitalised children were simply ones with overly concerned parents. 
These children therefore may not be an accurate reflection of the general population. 
Another way to obtain accurate pre-injury information would be with well-designed 
prospective studies like birth cohorts. In a large birth cohort study that included 1265 
children, McKinlay et al [185] challenged the hypothesis that children who have 
behavioural, cognitive problems or learning disabilities are more likely to experience 
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TBI and found that pre-injury behavioural problems were not a significant factor of TBI. 
This result was in agreement with other studies using prospectively collected data 
[186, 187]. Although the study identified three main risk factors of TBI (male sex, 
punitive parental style and number of adverse life events) the level of predictive 
efficacy of the statistical model suggested a number of unaccounted risk factors. It is 
hypothesised that children from stressed families are likely to be less supervised and 
therefore their exposure to TBI events is higher. 
There is however agreement regarding the behavioural outcome following TBI. 
Changes of both internalizing (anxiety/depression [188, 189], withdrawal [190], somatic 
complaints) and externalizing behaviours (aggression [175, 191], rule breaking and 
intrusive) have been reported. Whether pre-existing or not, inattention is among the 
most commonly reported disorder post TBI as almost half of children developed 
symptoms of ADHD after TBI [192, 193]. Interestingly in children with pre-injury ADHD, 
their symptoms persist without the fluctuations described in TBI children without a pre-
injury diagnosis of ADHD [194]. Children with TBI are at a much greater risk to develop 
new onset mood or and/or anxiety disorders as they are often left with residual 
cognitive, physical, behavioural and emotional deficits, all of which interfere with 
reintegration into the community (almost half of them at 6 months post TBI compared 
to 14% in children with orthopaedic injuries [195]). One year post injury, 10% of TBI 
children fulfil criteria for posttraumatic stress disorder (PTSD) which include avoidance, 
re-experiencing and hyperarousal [196]. Age at injury may affect the outcome in 
different ways. Younger children with TBI appear more vulnerable to anxiety disorders 
[197] but older ones are more vulnerable to depression [198]. 
Aggression and rule breaking behaviour are prevalent in children with TBI both before 
(explaining the higher TBI event risk described in some studies but not in prospective 
birth cohorts) and after their injury. In a prospective study of fifty children hospitalized 
after TBI, injury severity predicted oppositional defiant disorder (ODD) symptomatology 
at 2 years after injury but psychosocial factors appeared to play a greater role in the 
development of ODD symptomatology in the first year after TBI [199]. Children with 
ODD are also more likely to use aggression to resolve social conflicts rather than 
behaviours that preserve relationships with both peers and family [200]. All of the 
above attributable to TBI disorders can still be present several years post-injury [172, 
182] and predispose these individuals to violent crime [201] or further mental health 
disorders [202]. 
Depressive symptoms shortly after TBI are not more common or different to the 
symptoms experienced by other children hospitalized for other trauma (orthopaedic) 
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reasons. This suggests that the hospitalization experience rather than the type of injury 
determines the emergence of depressive symptoms [188]. At follow-up however, TBI 
children are more likely to report more depressive symptoms with socioeconomic 
status being a significant outcome moderator. Most studies suggest that TBI increases 
the risk of depressive symptoms (10-25% up to 2 years post TBI), especially among 
more socially disadvantaged children. 
The relationship between GH secretion and depression is multifactorial. Considering 
that GH secretion occurs mainly during sleep and patients with depression have 
problems with sleep quality (falling asleep and sleep maintenance), it has been 
hypothesised that GH secretion is reduced in these patients. Although some studies in 
adult patients with depression support this hypothesis [203, 204] other studies have 
failed to find blunted GH secretion in depressed adults [205, 206]. Studies in children 
and adolescents measuring spontaneous GH secretion are also inconclusive. De Bellis 
et al [207] in a study of 38 medically fit children with prepubertal major depression and 
28 healthy control children, found that depressed children had lower cortisol secretion 
during sleep but GH secretion did not differ between groups. Subgroup analysis 
showed lower GH secretion in depressed females when compared to depressed 
males. These findings were not replicated by Kutcher et al [208] in a smaller group of 
depressed adolescents who demonstrated higher overnight GH secretion compared to 
a matched (age, gender, pubertal stage, weight) control group. Using pharmacological 
stimuli (insulin induced hypoglycaemia, clonidine and GHRH) Ryan et al [209] 
demonstrated blunted GH secretion in 38 medically fit children with major depressive 
disorder. Although the study supported existing evidence demonstrating a relation 
between childhood depression and GH dysregulation, there was no clear explanation 
for the blunted GH response to GHRH suggestive of impaired pituitary responsiveness 
which was also described by Dahl et al [210]. 
Studies in adults with GHD have not found a relationship between measures of GH 
and psychometric tests [211]. The observed improvement of psychosomatic complaints 
and depression following GH treatment is therefore possible to be secondary to the 
associated improvement in somatic effects with GH replacement. Most studies overall 
suggest that TBI increases the risk of depressive symptoms (10-25% up to 2 years 
post TBI), especially among more socially disadvantaged children.  
1.6 TBI AND NEUROIMAGING 
Studies of paediatric TBI using conventional neuroimaging techniques have explored 
the location and volume of focal lesions or volumetric changes in total brain volume, 
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grey or white matter. It is not clear however that the methodology of cerebral 
localization [212] (the concept that specific areas of the brain control or mediate certain 
behaviours) which is based on adult based models can be extrapolated to the 
developing brain, which has less fixed functional organisation [213]. 
CT is widely available and is still regarded as the first line neuroimaging modality in 
TBI. Short acquisition time and high sensitivity in detecting life-threatening conditions 
requiring immediate intervention while allowing easy access to medical staff during the 
scan are important advantages over MRI (magnetic resonance imaging). 
Studies where CT brain scans were performed in children with inflicted or non-inflicted 
TBI suggest that the modified GCS, duration of impaired consciousness, number of 
intracranial lesions are predictive factors of Glasgow Outcome Scale and cognitive 
outcome after one year with pupillary abnormalities being associated with poorer motor 
outcomes [214]. However, other studies, using more advanced techniques [voxel-
based morphometry (VBM)], did not demonstrate persisting morphometric changes of 
the pituitary gland and hypothalamus in the long-term (minimum of 7 years post TBI) in 
paediatric TBI survivors without endocrine dysfunction requiring intensive care 
treatment [215]. 
Although CT provides important and timely information, MRI is able to identify 
significantly more intraparenchymal lesions [216, 217] but acquisition time is longer 
and will usually require the paediatric patient to be sedated. The identification however 
of more TBI related lesions has significant implications in regards to outcome 
measures and prediction models. Centrally located lesions appear to be directly 
associated to severity of acute impairment of consciousness and inversely related to 
functional outcome measures (Glasgow Outcome Scale and the Vineland Adaptive 
Behaviour Scale) [217]. Children with thalamic and/or basal ganglia injury are three 
times more likely to develop secondary ADHD when compared to children without 
injuries in those regions [218]. 
The frontal brain region, which is the most frequent – not centrally located – area of 
damage following TBI is believed to be associated with executive function, attention, 
and affections [219-221]. Although research in adults has clearly linked frontal lobe 
region integrity (prefrontal cortex) to measures of executive function [222], this 
functional specificity for executive processes has not been convincingly demonstrated 
in children where the volume of extrafrontal (rather than frontal) lesions and total 
number of lesions was predictive of executive functioning [223]. Frontal white matter 
damage correlated with novel depression 6 months after injury [198]. Diffuse cerebral 
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atrophy following paediatric TBI was associated with worse global outcomes (Glasgow 
Outcome Scale). Brain tissue preservation correlated positively with recovery 
outcomes [178].  
These findings suggest that in paediatric TBI, diffuse/extensive rather than localized 
brain injury may be more important with regard to predicting outcomes. Consequently, 
the focus has been in developing neuroimaging techniques that generate not only 
more detailed images of grey and white matter but also provide measures of function 
integrity. 
Diffusion Weighted Imaging (DWI) by using differences in diffusion/mobility of protons 
within the brain can reveal a greater extent and degree of abnormality than that seen 
with T2-weighted and FLAIR sequences [224]. The mapping of the diffusion process in 
biological tissues has been shown to be more sensitive to the diffuse white matter 
damage that often occurs in TBI [225-228]. DWI also allows differentiation between 
cytotoxic and vasogenic oedema (both associated with DAI which is seen following 
TBI), the latter or which may be reversible with appropriate treatment [229]. 
Following from DWI, Diffusion Tensor Imaging (DTI) measures the directionality of 
proton diffusion within the brain, providing information about white matter integrity 
through the calculation of Fractional Anisotropy (FA). High FA (range 0-1) corresponds 
to maximal anisotropic diffusion, as seen for example in intact, tightly packed fibre 
tracts [226]. FA across a number of white matter tracts was found to correlate with 
severity of TBI in children at least 1 year after TBI [230]. 
1.7 INTRODUCTION SUMMARY 
TBI remains the leading cause of acquired neurological morbidity in children. Data 
collected from registers of all children admitted to hospitals with TBI represents a very 
conservative estimate of the true incidence of TBI in childhood and an overestimate of 
the proportion of severe TBI, as most cases of mild TBI are not seen in hospital. Large, 
population-based studies estimate the incidence of TBI to be 550-800 per 100,000 
people per year with almost a third of the general population having sustained TBI by 
25 years of age. 
Although severe TBI has been reported to be associated with poor health-related 
quality of life, depression, fatigue, behavioural changes and sexual disturbances not 
much is known about the long term (10 year) prevalence of neuroendocrine 
dysfunction in children. Studies in adults report long-term prevalence of post traumatic 
hypopituitarism ranging from 10% to 70% which reflects the significant differences in 
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methodology and interpretation of tests used to measure outcomes (cognitive, 
behaviour, quality of life and endocrine). Similar variability is seen in the small number 
of available paediatric studies which in addition are limited by the small number of 
participants. Overall, post-TBI hypopituitarism was less prevalent in studies that 
included patients with mild TBI but indicators of trauma severity (GCS, skull fracture, 
DAI) have not been consistently reported to be associated with TBI related 
hypopituitarism. As there is a considerable overlap between post-TBI symptoms and 
chronic hypopituitarism, it has been hypothesised that TBI related morbidity could be 
secondary to undiagnosed and subsequently untreated hypopituitarism stressing the 
need for common diagnostic criteria to facilitate comparisons between studies and 
treatment outcomes. 
For practical reasons dynamic, non-physiological tests are being used to diagnose GH 
deficiency. These were initially developed for the endocrine assessment of specific 
patient groups (short children, cancer survivors etc.) but it is not known if these tests 
are appropriate for TBI patients where the “true” risk of chronic hypopituitarism is 
unknown. Measurement of spontaneous GH hormone secretion facilitates analysis of 
hormone pulsatility which could be used for assessing GH status in TBI survivors as it 
has already proven helpful in clinical settings such as oncology patients treated with 
cranial irradiation or slow growing children with normal GH response to dynamic testing 
(neurosecretory dysfunction). 
The clinical manifestations of hormone deficiencies due to post-traumatic 
hypopituitarism can be obvious or very subtle especially with mild TBI. In addition any 
symptoms or signs of hypopituitarism may be masked by the cognitive, physical, 
and/or behavioural sequelae secondary to damage to other regions of the cortex or 
diffuse axonal injury. Advances in neuroimaging techniques suggest that in paediatric 
TBI, diffuse/extensive rather than localized brain injury may be more important with 
regard to predicting outcomes. 
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2 CHAPTER 2 (STUDY DESIGN) 
HYPOTHESES 
• Potentially treatable long-term endocrine dysfunction occurs in a significant 
proportion of children following severe/moderate TBI, and possibly mild TBI. 
• There is an association between neuro-endocrine dysfunction in TBI children and 
impaired physical, cognitive and psychological functioning and reduced health related 
quality of life (HRQL). 
2.1 AIM 
The aim of KHINES was to assess the long-term prevalence of endocrine dysfunction 
and the impact on health, cognition, emotional/behavioural status and health related 
quality of life in an established, well-characterised cohort of severe/moderate and mild 
TBI children and adolescents when compared to non-injured controls. 
2.2 OBJECTIVES 
a. Endocrine assessment of: 
a. GH (Growth Hormone) status in the severe/moderate TBI group using: 
i. provocation tests 
ii. overnight venous sampling 
b. HPA (Hypothalamus-Pituitary-Adrenal) axis function with: 
i. provocation tests 
ii. overnight venous sampling (in severe/moderate TBI group only) 
iii. Non-invasive (salivary) sampling for cortisol (all groups). 
b. The relationship of neuro-endocrine function post-TBI to detailed measures of 
injury severity, including neuroradiological imaging. 
c. The relationship of neuro-endocrine function post-TBI to detailed and 
longitudinal measures of outcome including cognition, psychological status and 
Health-Related Quality of Life (HRQL).  
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2.3 PROJECT APPROVAL  
Sponsorship was obtained from the University Hospitals Bristol National Health (NHS) 
Foundation Trust in October 2009 (Appendix 6.1.1) 
• The study was approved by the South West Research Committee 4 on 13 April 
2010 (appendix 6.1.2) and University Hospitals Bristol Research and Development 
Department on 18 June 2010 (appendix 6.1.3). 
2.4 DATA PROTECTION 
Data were collected and retained in accordance with the Data Protection Act 1998. 
Identifiable personal information was anonymised, with codes accessible only to the 
investigators of the study, to ensure confidentiality. All study data have been stored 
according to local research policies and standards from Good Clinical Practice 
Guidelines on the University Hospitals Bristol, NHS server and accessible only from 
Trust intranet. Data were collected with the help of a Case Record File and transferred 
to an Access Database. Non-patient identifiable data were also backed up in an 
encrypted USB flash drive registered to ND. Data was entered in a Microsoft Access 
Database and exported for analysis with SPSS. 
2.5 STUDY PARTICIPANTS 
All individuals who had participated to the Kids’ Head Injury Study (KHIS, 2002-2004) 
and had agreed to participate in any further TBI related studies were eligible for 
recruitment. KHIS was a prospective study of outcome in children with severe, 
moderate and mild TBI for whom detailed data were available concerning the severity 
and mechanism of TBI and outcome. A research psychologist who had been a 
member of the original KHIS team made initial contact with participants. Failing initial 
contact by telephone, participant details were verified and updated if necessary by 
contacting their primary care physician followed by an invitation letter to their last 
known address if they could not be contacted by phone. Informed consent/assent was 
obtained from participants and parent/legal guardian as appropriate for age. 
Participants were divided into 3 groups. 
 Group 1 (control group) 
Control participants in KHIS were non-injured school children matched for 
age, sex, socio-economic status based on the Income Deprivation Affecting 
Children Index (IDACI) and pre-TBI academic attainment using the “best 
friend model”. In this model KHIS participants were asked to nominate a friend 
 
31 
or acquaintance of the same sex and age who were at the same school. 
Friend controls are presumed to be more motivated, inadvertently matched on 
characteristics not intended as matching factors and have higher response 
rates compared to general population controls [231, 232]. 
 Group 2 (mild TBI) 
Participants with admission Glasgow Coma Score [2] (GCS) 13-15 and normal 
neuroimaging) 
 Group 3 (moderate/severe TBI) 
Participants with Moderate/Severe TBI (admission GCS 3-8 for severe and 9-
12 for moderate TBI) or injury related abnormalities on initial neuroimaging 
even with GCS 13-15 . 
Exclusion criteria were failure to obtain informed consent, pregnancy, history of cranial 
irradiation, significant pre-TBI endocrine dysfunction (excluding transient 
endocrinopathy e.g. transient hypothyroidism, recovered adrenal suppression from 
steroids), medical or psychological problems not related to TBI (including alcohol and 
drug abuse) that could disturb interpretation of results and history of further TBI. In 
addition, participants on any steroid preparation (topical or systemic) were asked to 
stop this before the tests where clinically possible. If this was not clinically acceptable 
the endocrine tests were either postponed (if a short course of treatment was involved) 
or were not performed. Shift workers were tested at least a week after their last night 
shift and alcohol/drug intake was not permitted for a minimum of 24 hours before any 
assessment. Participants who had travelled across more than three time zones were 
seen at least 3 months after their return in the UK. 
Power calculations for the endocrine assessments were based on a conservative, 
estimated prevalence of GH deficiency in the general population of 1:10,000 (1:3,000 – 
1:17,000 from large population studies) [233, 234] and 10% in the moderate/severe 
TBI group. The number of participants needed to demonstrate with a power of 80% a 
statistically significant difference (5% level of significance) was 16. 
For salivary cortisol assessment, where a control group would be available, at least 17 
patients were needed per group in order to demonstrate with 80% power, a difference 
of one standard deviation (SD) between morning salivary cortisol levels in TBI patients 
and controls. 
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2.6 ENDOCRINE INVESTIGATIONS 
2.6.1 Clinical Assessment 
Participants were studied at the Bristol Royal Hospital for Children and had a baseline 
clinical assessment, including pubertal staging according to Tanner method [235], and 
symptom review with questionnaires for measures of HRQL and health status. All 
assessments were done by the same experienced research doctor (ND). 
2.6.2 Anthropometry 
Height 
Measurements included morning height using a daily-calibrated Harpenden® wall 
mounted stadiometer. Shoes, hair clips and braid were removed. Participants were 
positioned with feet together, flat on the ground, heels touching the back plate of the 
measuring instrument, straight legs, buttocks and scapulae against the backboard and 
arms loosely at their side. Head was positioned so that the lower margins of the orbit 
and external auditory meati were in the same horizontal plane. While applying gentle 
pressure and holding their mastoid processes to stabilise the head in the correct 
position, participants were asked to breathe normally and the headboard was placed 
on the top of their head. Height was recorded to the nearest mm after full exhalation. 
The measurement was repeated three times and the average rounded to the nearest 
mm. 
Weight 
Weight was measured to the nearest 0.1 kg with participant wearing light indoor 
clothing after removing shoes/slippers and pocket contents. The scales used were 
regularly calibrated with a traction weight. 
Body Mass Index (BMI) 
BMI was calculated as weight (kg) divided by the square of height. Weight, height, and 
BMI were corrected for age and gender using SDS from the Cole’s LMS method [236, 
237]. 
Waist circumference was taken during expiration at the narrowest waist level, or if this 
was not apparent, at the mid-point between the lowest rib and iliac crest using a cloth 





Methods to measure body fat can be divided in two categories: “reference” (body 
density, total body water, DEXA [dual-energy X-Ray absorptiometry), MRI] that 
measure a physical property of the body or “prediction” methods (skinfold thickness 
[238] and bioelectrical impedance analysis [BIA]) that use regression analysis to give 
an estimate of the “reference” method outcome [239]. Skinfold thickness has been 
found to provide an accurate estimate of total body fat when compared to DEXA 
including in GH deficient patients [240]. 
BIA estimates total body fat indirectly by using electrical current tissue resistance to 
measure total body water and by extrapolation fat free mass. Total body fat is then 
calculated as the difference between body weight and fat free mass [241]. BIA, 
especially when using recently developed analysers, provides a quick, safe and 
accurate method of measuring total body fat. Limitations are mainly dependent on 
hydration state including fluid shifts between different areas of the body throughout the 
day [241]. In healthy, normal weight, young adults this is not an issue and bioelectrical 
impedance is an accurate tool to estimate total body fat regardless of their activity level 
[242]. 
Skinfold thickness was measured over three sites (biceps, triceps and abdomen) using 
a Holtain® skinfold calliper. Measurements were taken on the right side for 
consistency. If for any reason measurements needed to be taken on the left side 
(injuries, amputation, deformities) this was recorded. All measures were performed by 
the same researcher. The mean of two measurements were taken and if they differed 
greatly (over 20%), a third was done and the median value was recorded. 
For bioelectrical impedance analysis, a Tanita® Body Composition Analyser (Model 
BC418, Tanita, Arlington Heights, Illinois) was used. Measurement of body 
composition is done using a constant, high frequency current (50kHz, 500μA). The 
electric current is supplied from electrodes on the toes and fingertips of both 
extremities. To calculate body fat percentage, the Body Composition Analyser uses 
normative data acquired from a representative Western population using DEXA and 
regression formula using height, weight, age, and impedance between right hand and 
foot as variables. Body fat percentage, fat mass, and fat free mass for individual parts 
and for the entire body calculated with this method, correlate strongly with DEXA, 
hydrostatic weighing and total body potassium results [243, 244]. Body composition 
measurements attained by bioelectrical impedance are therefore highly reproducible. 
Factors that can affect readings include hydration status (readings are usually highest 
in the morning). For consistency all body fat percentage readings were taken before 
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noon. In participants admitted for overnight studies measurements were taken the 
following morning before the stimulation test. Readings were taken with light clothing 
after socks or stockings were removed. Soles were inspected to ensure there were 
clean before stepping on the analyser. 
2.6.2.1 Statistical analysis of anthropometry 
Standard deviation scores (SDS) according to British references [236, 245] were used 
for comparisons. Differences between participant and non- participant characteristics 
were assessed by a χ2 test (for categorical variables) or t test (for continuous 
variables). A level of p<.05 was considered statistically significant. 
When analyses included comparisons between the 3 study groups (control group 
versus mild TBI versus moderate/severe TBI) these were performed by analysis of 
variance followed with pairwise comparisons (two tailed t-test with Bonferroni 
adjustment) when a significant difference was indicated. Non-parametric tests were 
used (Mann Whitney U for 2 groups and Kruskal-Wallis for 3 or more groups) to 
compare for dependent variables that were continuous but did not meet requirements 
of parametric equivalents. These were followed by pairwise comparisons (adjusted for 
the number of comparisons made) when the overall test showed significant differences 
across samples. 
2.6.3 Endocrinology 
2.6.3.1 Baseline Endocrine 
Baseline samples were drawn before the start of the ITT for analyses of free thyroxine 
(fT4), TSH, testosterone (men), oestradiol (E2, women), LH, FSH, prolactin (PRL), 
IGF1 and IGF-BP3. Three of the tested female participants were on oral 
contraceptives. 
2.6.3.2 Stimulation test 
The hypothalamic–pituitary–adrenal and GH–IGF1 axes were evaluated by an insulin 
tolerance test (ITT) if there were no contraindications (epilepsy or history of seizures, 
heart disease, pregnancy). The ITT was performed after completion of overnight 
sampling by administering soluble insulin i.v. (Actrapid, Novo Nordisk, Denmark) at a 
dose of 0.15 U/kg or 0.10 U/kg if there were concerns of multiple pituitary hormone 
deficiency. Participants were supervised constantly during the test by the research 
doctor and specialist endocrine nurse and hypoglycaemia was treated with oral 
glucose followed by a carbohydrate rich snack (biscuit or bread) or i.v. (2ml/kg of 10% 
Dextrose). Serum cortisol and GH were measured at the following time points: -15, 0, 
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30, 60, 90 and 120 min (insulin was given at time point 0). Between 5 and 30 min after 
insulin administration, serum glucose was determined every 5-10 min and every 15 
min thereafter. A successful test was defined by a blood glucose nadir lower than 2.2 
mmol/l and clinical symptoms of hypoglycaemia. Peak GH values used for diagnosing 
GHD differed depending on age group. A cut-off of <3 mcg/l was used in adults [246], 
<7 mcg/l in children and <5 mcg/l [77] in study participants in the transition phase – the 
5-7 year period from late puberty to full adult somatic maturation [247]. Cortisol levels 
>500 nmol/l were considered to reflect normal GH and ACTH function [248]. 
2.6.4 Spontaneous GH and cortisol secretion 
For assessing spontaneous GH and cortisol secretion participants were admitted for a 
12-hour overnight venous profile in a special investigation unit, detached from clinical 
wards. An intravenous cannula was placed after application of local anaesthetic in a 
forearm vein. Blood sampling started at least 1 h after catheter insertion to avoid 
artefactual effects related to the venepuncture stress and continued for every 15 
minutes. Sampling was performed with every effort not to disturb the participant and 
the IV line was kept patent with 2ml flushes of normal saline after sampling. All 
participants were ambulatory and encouraged to continue with their normal activities 
until their usual bedtime and had an age-appropriate meal. They were asked not to eat 
or drink anything after midnight, except water in preparation for the following mornings 
GH stimulation test. Participants were free to turn off the lights at their usual sleep 
times. During bedtime hours, the lights were turned off. Sleep status was recorded 
during sampling. Participants were allowed to wake up spontaneously in the morning. 
Total volume of sampled blood was less than 100 ml. Blood samples were kept at 5oC 
until completion of the overnight sampling and following centrifugation all samples were 
stored at -70oC until analysis (within 3 months). Assays were performed in duplicate, 
and each subject’s sample was run in one batch to minimize inter-assay variance. 
2.6.4.1 Statistical analysis for hormone profiles 
Integrated GH and cortisol concentration was calculated as the area under the GH 
curve using the trapezoidal rule. Parameters of GH and cortisol pulsatility were 
analysed with regard to concentration and secretion. The absolute GH nadir was 
assumed to reflect basal GH secretion. Wave form–dependent deconvolution analysis 
of the 12-h GH and cortisol profiles was used to calculate pulse frequency and 
secretion profile. Non-parametric tests were used (Mann Whitney U for 2 groups and 
Kruskal-Wallis for 3 or more groups) to compare dependent variables that were 
continuous but did not meet requirements of parametric equivalents. These were 
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followed by pairwise comparisons (adjusted for the number of comparisons made) 
when the overall test showed significant differences across samples. 
In the absence of a control group for the overnight GH profiles, normative data from 
other studies using the same GH assay were used as a guide. The study from Nindl et 
al [249] that included participants with physical characteristics (age, BMI, body fat) 
similar to the KHINES mod/sev TBI group was selected. 
2.6.5 Salivary cortisol 
Several research studies have determined that saliva can be used to measure reliably 
cortisol levels [250]. More recently salivary cortisone has been shown to closely reflect 
free serum cortisol levels with the added advantage of being unaffected by cortisol 
binding globulin changes and being able to identify the rare patient with contamination 
of the salivary sample with topical steroids [251] [252]. Salivary samples were collected 
using Salivette® Cortisol (Sarstedt AG & Co) synthetic swabs. These are designed for 
measuring free cortisol and require a small volume of saliva (less than 1ml). Written 
instructions on how to collect the samples were handed to the participant on their first 
appointment followed by a demonstration [Appendix page Error! Bookmark not 
defined.]. Participants kept the swabs in their mouth for a 2-min period to collect saliva 
passively and then the swab was returned to the salivette tube, sealed and preserved 
at the participants’ domestic fridge. After all samples were collected they were posted 
or delivered in person to our laboratory in insulated packs and stored at -20oC until 
time of assay. Participants were instructed not to collect saliva when they were ill, had 
a cold, headache, or taking any medication. 
In order to assess the diurnal rhythm of cortisol, 4 samples were collected each day for 
3 days at waking, 4-6 hours, 8-10 hours, and at bedtime (all samples synchronised to 
the first morning sample). For assessing the response to physiological stress (cortisol 
awakening response [CAR]), cortisol samples were collected 30 minutes after 
awakening. Although the CAR is not an orthostatic response and is not influenced by 
morning activities [131], for uniformity we advised all participants to collect the first two 
samples while still in bed. Absence of diurnal variation was defined when the ratio of 
the first morning sample to the fourth or fifth sample (8-10 hours post awakening) was 
less than 0.5 [253]. HPA axis feedback was assessed with a dexamethasone 
suppression test. Dexamethasone 0.3 mg/m2 was administered orally at bedtime and 
three more salivary samples were collected on the final day at 8am, 12am and 4pm. 
Participants were given no direction as to when to wake up – this was left to their 
convenience. Samples were taken before or at least 30 minutes after drinking or 
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brushing teeth in order to prevent damage to the oral mucosa and contamination with 
blood. Eighteen samples were collected over 4 days. 
2.6.5.1 Statistical analysis for salivary cortisol 
Repeated measures ANOVA was performed to compare the salivary cortisol profiles of 
severe/moderate and mild TBI groups with the control group. Analyses were done with 
and without participants having a negative CAR on all three days of sampling. 
2.6.6 Assays 
All samples were assayed by biochemistry laboratories, which had full Clinical 
Pathology Accreditation (CPA). All analysis was done at the Bristol Royal Infirmary, 
University Hospitals Bristol, UK except from IGF-1 and IGFBP-3 that were assayed at 
Guildford biochemistry laboratory. 
Serum GH concentrations were measured using a commercial immunoassay (“hGH”, 
Roche Diagnostics GmbH) for in vitro quantitative determination of human GH forms 
with molecular masses of 20 kDa and 22 kDa. The electrochemiluminescence 
immunoassay (ECLIA) was used on a Cobas e601 immunoassay analysers. Intra- and 
inter-assay coefficients of variation (CV) were 1.9% and 3.0% at GH concentrations of 
0.163mcg/L; 2.0% and 3.0% at GH concentrations of 8.23 mcg/L. The limit of 
detectability was 0.03mcg/L with a limit of quantitation of 0.05mcg/L (lowest analyte 
concentration that can be reproducibly measured with an intermediate precision CV of 
≤ 20%). 
Salivary cortisol and cortisone were measured with ultra-performance liquid 
chromatography-tandem mass spectrometry (Waters Acquity UPLC, Waters Quattro 
premier XE tandem mass spectrometer) with intra- and inter-assay CV of less than 
10% at 5-48 nmol/L of cortisol and less than 7% at 10-102 nmol/L of cortisone. 
Serum IGF-1 and IGF-BP3 measurements levels were measured by solid-phase, 
enzyme-labelled chemiluminescent immunometric assay (IMMULITE/IMMULITE 1000 
IGF-I). For IGF-1, intra-assay and inter-assay CV’s were under 4% and 8% 
respectively for concentrations between 6-120nmol/L. IGF-BP3 intra- and inter-assay 
CV’s were 5.6% and 9.9%; 3.5% and 7.5% at IGF-BP3 concentrations of 1.6 and 
6.8mg/L respectively. IGF1 and IGF-BP3 SDS were calculated from the reference 
range values. 
Glucose concentration was measured on a COBAS analyser (Roche Professional 
Diagnostics’ Products, Burgess Hill, West Sussex, UK) by Hexokinase method with 
intra- and inter-assay CV of under 1% over the whole measuring range. 
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TSH, FT4, LH, FSH, prolactin, oestradiol and testosterone were all measured by 
ECLIA with intra- and inter-assay CV of less than 5% over the whole measuring range 
except from testosterone intra- and inter-assay CV were less than 5% at the range 
between 2.4-45 nmol/L but 15% at 0.3 nmol/L. 
2.6.7 Deconvolution 
Pulse analysis methods were introduced to assist in identifying hormone pulses in an 
objective way. Early methods such as Pulsar [254] and Cluster [121] did not provide 
detailed information about the secretory events or the substrate/hormone elimination 
and were still subject to operator measurement error. AutoDecon [255] automates the 
procedure and introduces statistical verification of secretory episodes. 
2.6.7.1 AutoDecon 
The pattern of GH and cortisol secretion was analysed using validated Deconvolution 
software (AutoDecon). The automatic algorithm identifies statistically significant 
secretory peaks using the assay as a scale factor rather than arbitrary defining a pulse 
as an increase in growth hormone exceeding the preceding nadir by 20% [256]. It also 
discriminates (by applying a multiple-parameter deconvolution model) the amplitudes, 
durations, interpulse intervals of all statistically significant underlying secretory bursts 
from the plasma hormone concentrations. The program does not make any 
assumptions on timing, size or duration of secretion events but assumes that secretory 
events follow a Gaussian distribution and elimination follows a single compartment 
pharmacokinetic model 




where HL is the elimination Half Life. 
 
The mathematical model for the time course of the hormone concentration is: 




where C(t) is the hormone concentration at time t, S(t) is the secretion at time t and E(t-
τ) the elimination from serum as a function of time. 
Using a weighted, non-linear, least-squares method the software fits the above 
equation to experimental data by adjusting parameters of secretion and elimination and 
reporting the values of determined parameters that are statistically significant – i.e. 
having the highest probability of being correct. When one or more these parameters 
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are known in advance, they can be fixed and the remaining ones will be altered 
automatically in order for the mass of each peak to remain the same. 
The triage module of Autodecon applies the above deconvolution model in cycles and 
recursively assigns the locations of secretion events (i.e. peaks) after performing a 
series of statistical tests using a probability level of 0.05. Peaks are added one at a 
time, starting at the optimal location to lower variance-of-fit remains low. All peaks are 
then tested and removed if not statistically significant and the process is repeated until 
no additional secretion event can be added.  
AutoDecon uses the following settings when initialized: 
1. basal secretion set equal to zero 
2. concentration at time zero set equal to zero 
3. elimination half-life (HL) set to any physiologically reasonable value 
(approximately 10-20 minutes for GH) 
4. standard deviation of the secretion events (Secretion SD) set to one-half of the 
data sampling interval, and 
5. zero secretion events 
After all secretion events are added and the parameters above are estimated, 
AutoDecon will examine differences (residuals) between the data points and the fitted 
curve for fitting problems – usually failure to identify a partial secretion event at the 
beginning or end of the times series. When this is observed, that data point is removed 
and the AutoDecon is repeated without the offending data but with current initialization 
values. AutoDecon will highlight outliers as data points being statistically different from 
the expected. These are data points with a Z score of the particular residual greater 
than 4. Outliers may be the result of incorrect data entry or simply a reflection of 
inherent measurement uncertainty within experimental data. In any case, the cause for 
the outlier has to be investigated before removing from the data series. 
In order to estimate the precision of the measured hormone concentrations (as 
typically most studies use only a small number of replicate samples – usually 2), 
AutoDecon uses a weighting factor based on a variance model that takes into account 
parameters of the hormone assay which are well known as they are part of the quality 














where CV is the % coefficient of variation at the optimal range for the assay, MDC is 
the minimal detectable concentration. 
A typical output of the use of the AutoDecon algorithm is seen on Figure 10. 
 
Figure 10 Sample of AutoDecon output 
At the top (Hormone Concentration) a time series of data points with vertical error bars, with the solid 
curve corresponding to the predicted concentration is plotted. The asterisk at the top of the panel marks 
the location of the single secretion event. In the middle panel weighted differences (residuals) between the 
data points ones calculated by AutoDecon. At the bottom (Secretion) is a representation of the calculated 
secretion pattern. The diamond in this panel marks the location of the next presumed secretory event, 
which was discarded because it was not statistically significant. 
The AutoDecon algorithm allows for non-equal data spacing and missing values. The 
area under the curve (AUC) was estimated from the level of the calculated baseline. 
The duration of a secretory pulse was defined as the time interval separating the 
preceding and following troughs and in each individual profile, the level of baseline 
secretion was estimated as the secretory rate necessary to maintain the baseline GH 
concentrations during the inter pulse intervals. For each significant pulse, pulsatile GH 
secretion was calculated by subtracting the baseline secretion from the total secretion. 
The amount of pulsatile GH secretion over a given time interval was determined by 
summing the amounts of pulsatile secretion in each of the significant pulses occurring 
during that time interval. 
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2.6.7.2 Approximate Entropy (ApEn) 
ApEn is a reflection of the regulation of a feedback network. It was developed as a 
single statistic to quantify the amount of regularity in time-series data which could not 
be measured with descriptive statistics like mean, median and variance. For example, 
the data series (70, 80, 70, 80, 70, 80, 70, 80, ….alternating 70 and 80) and (70, 70, 
80, 70, 80, 80, 80, 70, 80 ... randomly 70 or 80) have the same mean, median and 
standard deviation but are “different” in that the first series is "regular" and knowing 
one value gives insight into what the next value will be. 
Most biological processes have temporal irregularity and ApEn is a measure of how 
these processes are controlled [257]. Low temporal irregularity implies tight control and 
too strong control makes adaptation to changes in the environment difficult. For 
example a patient with complete heart block and fixed heart rate has not temporal 
irregularity and cannot adapt to changes, for example physical activity as he cannot 
increase his heart rate. The ApEn in this example would be close to 0. [258, 259]. 
In endocrinology ApEn has been used to distinguish acromegalic from normal pulsatile 
growth hormone release. Low irregularity implies tight control and high irregularity 
implies no control. For hormone time series, ApEn computed from secretion time 
series (for example after applying deconvolution methods to plasma concentration time 
series) enhances the discriminating ability of ApEn to identify endocrine states 





2.7 NEURO-PSYCHOLOGICAL AND HRQL ASSESSMENT 
Cognition and psychological assessments were undertaken by a team of student 
research psychologists under the supervision of an experienced clinical psychologist 
(HM). Measures of HRQL and health status were assessed by ND. All tests are listed 
in Table 2. 
  Age Self Proxy 
Cognition WASI-II (Wechsler Abbreviated Scale of Intelligence) 7+  
  TEACh (Test of Everyday Attention for Children) 17-  
  TEA (Test of Everyday Attention) 17+  
  CMS (Children’s Memory Scales) 17-  
  WMS (Wechsler Memory Scales) 17+  
  Wechsler Quicktest 17-  
  WRAT-4 (Wide Range Achievement Test) 17+  
Psychology Youth Self report (11-18y ) 18-  
  Child Behaviour Checklist (CBCL) 18-  
  Adult Self Report (18-59y) 18+  
  Adult Behaviour Checklist (ABCL) 18+  
  Beck Depression Inventory (BDI-II) 13+  
  Beck Anxiety Inventory (BAI) 13+  
  Birleson Depression Scale 11+  
  Children's Impact of Event Scale 8+  
  BRIEF (Behaviour Rating Inventory of Executive Function) 18+  
  BRIEF for under 18 18-  
Health PedsQL All  
  Participation All  
  Fatigue/Sleep All  
 Health Utilities Index (HUI) All  
Table 2 List of tests used in KHINES for assessing cognition, psychological status, fatigue and health 
related quality of life. 
2.7.1 Cognitive outcome 
In children aged <16 years, verbal and non-verbal reasoning ability, executive 
functioning and attention skills was assessed using the Wechsler Intelligence Scales 
for Children (WISC-III-UK) [261] and the full range of subsets from the Test of 
Everyday Attention in Children (TEACh) [262]. Objective assessment was 
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supplemented with behavioural ratings of executive function using parent and child-
completed Behaviour Rating Inventory of Executive Function (BRIEF) questionnaire 
[263]. Memory functioning was assessed using the Children’s Memory Scales (CMS); 
academic achievement using the Wechsler Quicktest, incorporating Basic Reading, 
Spelling, and Mathematical Reasoning subtests. In young people aged >16 years, 
assessment, where necessary, employed analogues of the above tests utilising adult 
normative data (i.e. WASI-II, WMS, TEA, WRAT-4). 
2.7.2 Psychological & behavioural outcome 
Long-term psychological status in participants aged years was assessed using the 
following tools: 
 Youth self-report and parent-report forms of the Child Behaviour Checklist 
(CBCL) [264] 
 Beck Depression Scale [265] (or Birleson Depression Scale [266] if under 13 
years) and Beck Anxiety Scale [267], both of which can be used in adolescents 
[268], as well as adults 
 Children’s Impact of Event Scale [269, 270]. 
In young people aged > 19 years at the time of the study, assessment employed 
analogues of the above tests utilising adult normative data (e.g. Impact of Events 
Scale) and comparison with previous test scores made using statistical algorithms 
accounting for association between test scores across adult and child versions. 
2.7.2.1 Behaviour checklist and self-report 
The Achenbach System of Empirically Based Assessment (ASEBA) comprises a family 
of forms for assessing adaptive functioning and problems. Originating in research on 
child and adolescent problems ASEBA forms were extended to adults in the 1980s and 
1990s [271]. 
ASEBA items are designed to tap strengths and problems that are potentially relevant 
to a person’s need for help. They include Self-Report (children CSR, adult ASR) and 
Behaviour Checklist (children CBCL, adult ABCL). These parallel forms facilitate 
comparisons between people’s perceptions of their own functioning and other people’s 
perceptions of their functioning. Behaviours are broadly categorized as internalizing or 
externalizing. The Internalizing grouping consists of three syndromes 
(anxious/depressed, withdrawal, somatic complains) that are mainly within the self. 
Externalizing grouping consists of three other behaviour syndromes (aggressive, rule 
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breaking and intrusive) that mainly involve conflicts with other people and with social 
mores [272, 273]. 
Each item is intended to provide useful information in its own right, in addition to 
contributing to scale scores. Some adaptive functioning scales comprise items that are 
relevant to most people, such as relationships with friends and family. Other scales 
comprise items that are scored only for people for whom they have been relevant at 
some time in the preceding 6 months, such as relationships with spouse or partner and 
job functioning. 
The respondent rates each item as 0 = not true, 1 = somewhat or sometimes true, and 
2 = very true or often true, based on the preceding 6 months. Raw and T scores are 
calculated. T scores facilitate comparisons between respondents using different 
instruments (adult vs child). T scores of 70 for example corresponds to a score on the 
98th centile of the normative sample for participants of that age and sex. T scores for 
competence scales are truncated at the nondeviant end, therefore comparisons 
between respondents that are “healthy” should be done using raw rather than T 
scores. Internalizing, Externalizing and total competence T scores are not truncated 
and can be used for statistical analyses and comparisons without losing any of the 
differentiation.  
Finally, ASEBA items have been used to construct DSM-oriented scales for 
behavioural, emotional, and social problems. Although not diagnostic per se, a high 
score on a particular DSM-oriented scale should prompt a check to see whether the 
client meets criteria (impairment, age of onset or duration of problems) for any DSM 
diagnoses corresponding to that scale. Validity testing of these scales has shown that 
scores on the CBCL and YSR anxiety problems scale predicted DSM-IV disorders only 
moderately but scores on the affective problems scale corresponded closely to DSM-IV 
major depressive disorder and dysthymia [274]. 
2.7.2.2 Depression 
The Birleson Depression Scale was developed as a clinical instrument to assess the 
degree of depressive feelings in children and adolescents [275]. The questionnaire 
consists of 18 items and children are asked to judge the extent to which a particular 
item has applied to them in the course of the previous week. Items are scored 0, 1, or 
2 and a total score of 17 or above is seen only in children with a diagnosis of clinical 
depression. 
The Beck Depression Inventory – Second Edition (BDI-II) is a 21-item self-report 
instrument for measuring the degree of depression in adults and adolescents aged 13 
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years and older. The second edition includes additional items such as agitation, 
worthlessness, concentration difficulty and loss of energy that address DSM-IV 
depression criteria, which were not included in the first edition. Respondents are asked 
to endorse the most characteristic statement over the previous 2 weeks. 
BDI-II is scored by summing the ratings for the 21 items (4-point scale ranging from 0 
to 3). Cut-off scores depend on the characteristics of the sample and the clinical 
considerations for which the instrument is administered. A cut-off score of 17 or over 
yielded a 93% true-positive rate in a clinical sample from the University of 
Pennsylvania [276] but lower cut-off scores can been used if the purpose is to screen 
for possible cases of depression. Total score ranges of 14-19, 20-28 and 29-63 for 
mild, moderate and severe depression respectively were obtained from the same 
clinical sample. 
2.7.2.3 Anxiety 
The Beck Anxiety Inventory (BAI) was developed as a clinical instrument for measuring 
the severity of an individual's anxiety [267]. It consists of 21 items describing common 
symptoms of anxiety and uses a 4-point scoring scale (range 0 to 3). There is an 
overlap with the depression scale as measured by the BDI-II (even when 
encompassing anxiety and depression specific items only in “purified” versions of the 
BAI and BDI-II) suggesting that anxiety and depression seem to be inherently linked 
[277]. BAI is scored by summing the ratings for the 21 items (4-point scale ranging 
from 0 to 3). Total scores in the 8-21 range are suggestive of mild, 21-42 of moderate 
and over 42 severe anxiety. 
2.7.2.4 Impact of events scale (IES) 
Children and adolescents can react to single acute stressors but also to chronic 
stressful situations with a particular form of anxiety called Post-Traumatic Stress 
Disorder (PTSD). The IES was developed to monitor the main phenomena of re-
experiencing the traumatic event and of avoidance and feelings associated with them. 
The original 15-item, four-point scale was reduced to 8 items as some of them were 
misinterpreted by children. The remaining 8 items still contain intrusion and avoidance 
items and the total score correlates highly with the total on the 15-item version (r>0.95, 
p<0.001). The IES is self-completed and the eight items are scored on a four-point 
scale with values of 0,1,3 or 5. The equivalent cut-off score indicating a high risk of 
PTSD for the shorter 8-item version is 17. 
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2.7.2.5 Behaviour Rating Inventory of Executive Function (BRIEF) 
BRIEF is an 86 item instrument designed to assess impairment of executive function. It 
has been shown to be useful in evaluating children and adults with a wide spectrum of 
developmental and acquired neurological conditions including TBI [278, 279]. Self and 
proxy rating forms are available. Two groups are assessed: behavioural regulation and 
metacognition. 
Clinical scales assessed in Behavioural regulation include inhibition (impulses control, 
stop behaviour), shift (ability to move freely from one activity/situation to another; 
transition; problem-solve flexibly) and emotional control (modulation of emotional 
responses). 
Clinical scales assessed in Metacognition include initiation (starting activity; generate 
ideas), working memory (holding information in mind for purpose of completing a task), 
organisation of materials (anticipating future events; setting goals; develop steps) and 
monitor (checking work; assessing own performance). 
Once raw scores for all scales are obtained, they can be converted to standard scores 
(T scores) with a mean of 50 and SD of 10. These scores are age and gender specific. 
Higher scores suggest a higher level of dysfunction.  
2.7.3 HRQL and health status 
Health related quality of life (HRQL) is the value assigned to duration of life as modified 
by the impairments, functional states, perceptions, and social opportunities that are 
influenced by disease, injury, treatment or policy [280]. In assessing HRQL, dimension 
or items (questions) are components of a domain of health. Instruments can be generic 
or disease specific. 
2.7.3.1 Paediatric Quality of Life Inventory 
HRQL was assessed using the generic Paediatric Quality of Life Inventory (PedsQL 
4.0) [281] a brief, standardized, modular instrument applicable for both children and 
adults. Generic core scales were designed to measure the core items of health as 
delineated by the World Health Organization and encompass: 1) physical functioning, 
2) emotional functioning, 3) social functioning and 4) school functioning. Although the 
PedsQL was derived from data collected on paediatric cancer patients, its reliability 
and validity was subsequently demonstrated on healthy and patient populations. It has 
been widely applied to children with a variety of acute and chronic conditions including 
TBI in childhood. In particular, the cognitive function scale of the PedsQL detected the 
largest differences among groups of children with varying severities of TBI [282]. 
Scores can be transformed to a 0-100 scale, so that higher scores indicate better 
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HRQL. An overall value of <69.7 (equivalent to one SD below the population mean) 
has been shown to represent poorer HRQL. PedsQL has been shown to be reliable: 
Total Scale Score (α=0.88 child, 0.90 parent report), Physical Health Summary Score 
(α=0.80 child, 0.88 parent) and Psychosocial Health Summary Score (α=0.83 child, 
0.86 parent). Both self and parent-report questionnaires were used in KHINES. 
For disease specific assessment the QoL-AGDHA, a one-dimensional, patient needs-
based HRQL instrument developed specifically to detect deficits in needs achievement 
in areas that are affected in adults with GHD was used. It consists of 25 ‘yes’ or ‘no’ 
questions [283]. The number of ‘yes’ responses constitute a score, with a high score 
denoting a poor HRQL. 
2.7.3.2 Chalder Fatigue Scale 
The Fatigue Scale devised by Chalder et al (1993) is a short, self-report measure of 
the severity of tiredness [284]. It produces a total score, with sub scores reflecting 
mental fatigue (4 items), and physical fatigue (7 items). The 11 items are rated on a 
four-option continuum, from “better than usual”, to “much worse than usual”. The 
responses are either assigned scores from 0 to 3 (Likert method) giving a maximum of 
33, or 0, 0, 1, 1 (bimodal method), giving a maximum of 11. A bimodal score of 3/4 was 
initially recommended for identifying significant fatigue [284] with subsequent studies 
estimating bimodal fatigue scores in community samples being 3.27±3.21 or 14.2±4.6 
using Likert method [285]. The scale has been validated in a general population study 
[286]. The validity of the questionnaire in assessing fatigue in the general population 
suggests that it is a useful tool for assessing fatigue in a variety of medical disorders. 
The limitations of the Fatigue Scale include its inability to distinguish between CFS and 
primary physical or cognitive dysfunction, which may confound interpretations of the 
responses [284].  
2.7.3.3 Health Utilities Index (HUI) 
The term utility corresponds to the value attached to a particular health state and is 
derived from judgments made by panels of the public, professionals or patients about 
relative values of different health states. The Health Utilities Index (HUI) is a system of 
measuring health status and is recognised to be a useful tool for reporting HRQL [287, 
288]. It was evolved in response to the need for a standardised system to describe a) 
the experience of patients undergoing therapy; b) long-term outcomes of disease or 
therapy; c) efficacy, effectiveness and efficiency of healthcare interventions and; d) the 
health status of general populations. HUI health-state attributes include vision, hearing, 
speech, ambulation, pain, dexterity, health-care, emotion and cognition. The major 
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criterion for selecting these particular attributes was the importance placed on each of 
them by members of the public. They are clearly distinguishable from one another and 
cover an extensive range of possible disabilities as each attribute has 3-6 levels that 
together describe almost one million unique health states. HUI attributes can be 
translated into a health utilities score by applying the utility formula of Torrance and 
colleagues [289]. HUI is scored using single- and multi-attribute utility functions and will 
allow for negative scores of HRQL that represent health states considered worse than 
dead. Utility scores have interval-scale measurement properties to support the use of 
HUI in constructing single summary indexes and to enable the use of parametric 
statistical techniques for making comparisons among clinical groups. The HRQL 
scoring systems provide utility scores on a generic scale where dead = 0 and perfect 
health = 1. Differences of 0.03 or greater in mean HUI overall HRQL scores have been 
reported to be definitely important, and differences as little as 0.01 may be meaningful 
and important in some contexts [290]. The overall HRQL score is determined using the 
HUI3 multi-attribute utility function (MAUF) is: 
=1.371*(lvl1*lvl2*lvl3*…lv8)-0.371 
Descriptive levels within HUI attributes were defined to be meaningfully different from 
each other when difference in utility scores between levels of an HUI attribute was 0.05 
or more. The lowest possible HUI3 multi-attribute utility is defined for the interval -0.36 
to 1.00. Single-attribute utility functions provide scores that describe the morbidity 
attribute by attribute. Each single-attribute utility function is defined on a scale from 
0.00 to 1.00 (0 for most disabled and 1 for no disability) and has interval scale 
properties allowing for comparisons between groups or to assess changes within 
groups over time. In brief, the overall health status of each person can be described 
using an 8-element vector (one from each of the eight attributes) and a single overall 
score of HRQL. 
The HUI-Mark 3 has been shown to discriminate between various child populations 
[291]. The health status measure provides information on the type and extent of 
disabilities whilst the utility scoring measures relative importance of disabilities, which 
is necessary for any health economic evaluations as outcomes, can be measured in 
quality-adjusted life years (QALYs). QALYs are estimated by multiplying the number of 
life years with a utility score that has the value 1.00 for “perfect health” and 0.00 for “a 
health state comparable to the value of death” as described previously. QALYs are 
particular useful to provide a common metric of burden of disease across the entire 
spectrum of diseases. 
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In addition, HUI measures have been shown to be responsive to changes of health 
status over time, which is an important property in detecting effects of recovery or 
treatment over time [292]. The HUI-3 can be used in all people age 5 and older in both 
clinical and general populations. Respondents were the participants and people other 
than the participant (usually parent or spouse) referred as “proxy”. Participants were 
asked to focus on their “usual” health without defining a specified period and explaining 
that short-time, self-limiting illnesses or injuries were not the point of interest. 
2.7.4 Child and Adolescent Scale of Participation (CASP) 
The Child and Adolescent Scale of Participation (CASP) has been developed to 
assess the extent to which children participate in movement-related, communication 
related and school-based social activities compared to children of the same age as 
reported by the carer. It was initially designed as part of the Child and Family Follow-up 
Survey (CFFS) to monitor outcomes of children with acquired brain injury [293] and 
subsequently, has been used alone or as part of the CFFS to examine participation of 
children other diagnoses [294]. 
The CASP consists of 20 ordinal-scaled items (applicable to children who are 5 years 
or older) in four subsections: 1) Home Participation (6 items), 2) Community 
Participation (4 items), 3) School Participation (5 items), and 4) Home and Community 
Living Activities (5 items). The 20 items are rated on a four-point scale: (4=Age-
expected, 3=somewhat limited; 2=Very limited; 1=Unable). 
CASP summary scores are created by summing all applicable item responses 
(maximum score 80), then dividing this number from the total possible score from all 
applicable items and then multiplying this number by 100 to conform to a 100-point 
scale. Higher scores indicate greater extent of age-expected participation. Item-level 
scores can be used to assess specific situations where for example mobility related 
participation is likely to be more affected. 
2.7.4.1 Statistical analysis of neuropsychological and HRQL data 
When analyses included comparisons between the 3 study groups (control group 
versus mild TBI versus moderate/severe TBI) these were performed by analysis of 
variance followed with pairwise comparisons (two tailed t-test with Bonferroni 
adjustment) when a significant difference was indicated. Non-parametric tests were 
used (Mann Whitney U for 2 groups and Kruskal-Wallis for 3 or more groups) to 
compare for dependent variables that were continuous but did not meet requirements 
of parametric equivalents. These were followed by pairwise comparisons adjusted for 
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CT brain scans previously performed as part of KHIS in severe/moderate TBI children 
during the acute post-injury phase were classified according to criteria/patterns 
described by Lobato et al [295]. Eight anatomical patterns emerged in a series of CT 
scans in 277 patients with severe TBI which provided stronger prognostic information 
when compared to the following four patterns of severe head injury: epidural 
haematoma, subdural haematoma, brain contusion and diffuse brain damage. The 
eight patterns included the following: 
Pattern 1: Pure extracerebral hematoma 
Pattern 2: Extracerebral hematoma plus acute hemispheric swelling 
Pattern 3: Single brain contusion, whether or not associated with a neighboring 
extracerebral hematoma 
Pattern 4: Multiple unilateral brain contusion whether or not associated with subdural 
hematoma 
Pattern 5: Multiple bilateral brain contusion 
Pattern 6: General brain swelling whether or not associated with small extracerebral 
hematoma 
Pattern 7: Diffuse axonal injury 
Pattern 8: Normal CT scans. 
Patients with acute hemispheric swelling after operation for a large extracerebral 
hematoma, multiple brain contusion (unilateral or bilateral) and diffuse axonal injury 
had worse outcomes. Conversely patients with normal CT scans, uncomplicated 
extracerebral hematoma, single brain contusion and general brain swelling had better 
prognosis [295, 296]. 
Unless contraindicated, all study participants were examined on a 3T MRI scanner 
(Magnetom Skyra, Siemens Medical Systems, Clinical Research and Imaging Centre, 
Bristol). 
Sagittal and coronal T2 TSE (TR/TE 4430/89ms; thickness 2mm; FOV 190; resolution 
0.5x0.5mm) and T1 weighted images (TR/TE 500/2.93; thickness 2mm; FOV 190) 
were obtained. These data sets were assessed visually by the same consultant neuro-




Assessment of the hypothalamic-pituitary axis included pituitary volume (using the 
ellipsoid formula i.e. volume = 4/6 *  * height * length * width) and height and 
thickness of the pituitary stalk. 
Volumetric and region of interest analysis (ROI) from obtained volumetric T1 data sets 
in participants who did not have any contraindication for having an MRI scan was 
performed using open source packages and toolboxes. The latest version of SPM 
[297] (SPM12, Statistical Parametric Mapping) developed at the University College 
London was used for most analyses in conjunction with CAT12 toolbox – an SPM12 
extension which provides computational anatomy options using Voxel-based approach 
(VBA) including voxel-based morphometry (VBM) but also surface-based morphometry 
(SBM) and deformation-based morphometry (DBM).  
VBA provide a voxel-based estimation of volume of a specific tissue compartment and 
as it “interrogates” the entire brain for abnormalities [298] it is particularly useful in 
evaluating TBI where brain abnormalities are not always fully delineated. 
VBM requires a number of pre-processing steps before data are appropriate for 
statistical analyses. Firstly, images have to be converted to a compatible format for 
processing which can be done with SPM12. Study imaging files were converted from 
DICOM (Digital Imaging and Communications in Medicine) to NIfTI (Neuroimaging 
Informatics Technology Initiative) format, and imported for pre-processing. 
Following conversion and in order to compare MRI data from different participants, all 
brain images were spatially registered in the same 3D space (normalization). This was 
done using a template defined by the Montreal Neurological Institute (MNI152 or 
MNI305). In general, the closer the images start out to the MNI template orientation, 
the better the outcome of the normalization. Alignment was further improved by using 
computational anatomy methods (DARTEL toolbox for SPM) [299] which can align fine 
structures across individuals in a way that takes into account anatomical constraints. 
Once images were normalised, tissue classification (segmentation of brain tissue into 
separate tissue compartments) allowed estimation of CSF, grey and white matter 
volumes. This was followed by scaling modulation so the total amount of grey matter 
was scaled back to the volume it would be in the original image. A sample of the output 






Figure 11 VBM output sample 
 
2.8.1 Statistical analysis of neuro-imaging 
When analyses included comparisons between the 3 study groups (control group 
versus mild TBI versus moderate/severe TBI) these were performed by analysis of 
variance followed with pair comparisons (two tailed t-test with Bonferroni adjustment). 
Non-parametric tests were used (Mann Whitney U for 2 groups and Kruskal-Wallis for 
3 or more groups) to compare for dependent variables that were continuous but did not 
meet requirements of parametric equivalents. These were followed by pairwise 
comparisons (adjusted for the number of comparisons made) when the overall test 




3 CHAPTER 3 – (RESULTS) 
3.1 PARTICIPANTS 
Exploration of the KHIS database identified 216 potential participants who were eligible 
for participation in this study. Forty-four participants were not contactable (11 moved 
outside the UK, one deceased in prison, five left home not registered with new GP, 27 
with updated contact details not contactable). From the remaining 172, 93 (54%) were 
not willing to participate in the study (in decreasing frequency due to time constrictions 
related to school/studies/work/family commitments, relocation outside the area, 
participating in other studies and court proceedings related to TBI in 2 cases). Six were 
excluded (two further TBI, 2 pregnant, 2 with non-TBI related endocrinopathy). All of 
the remaining 73 consented and 72 completed the study (one participant withdrew for 
family reasons) [ Figure 12 ]. 
 
Figure 12. KHINES recruitment flow chart 
 
There were no differences between participating and non-participating groups with 
regards to age, gender, time since TBI, duration of post-traumatic amnesia, days in 
intensive case or type of structural abnormalities on acute neuroimaging 
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  0.50 
Post traumatic amnesia days  10 1-99  10 1-77 0.81 
Intensive care days  1.5 0-22  0.5 0-30 0.20 
Age at TBI  11.7 0.2-16.7  11.1 0.1-17.5 0.45 
 
Table 3. Comparison between participating and non-participating patient groups 
 
The mechanism of injury in the 55 TBI participants is shown in Table 4. Two thirds of 
studied participants were male (n=49, 67%). Characteristics of study groups including 
age at injury and time from injury are shown in Table 5 
 
 




Table 4. Injury mechanism in TBI children 
 
Of the 72 participants 31 (43%) were categorised as moderate/severe TBI (GCS 
severe 3-8, moderate 9-12), 24 (33%) mild TBI (GCS 13-15) and 17 (24%) were 
healthy controls. Three female participants were on oral contraceptive. No participants 
were on treatment for epilepsy. 
Mechanism of injury n=55 
Fall *23 















Table 5. KHINES Study group characteristics 
  
KHINES groups Mean SD Range 
Control     
Age at evaluation (years) 18.5 5.5 10.9 - 27.6 
Mild TBI     
Age at evaluation (years) 17.8 5.0 9.4 - 26.3 
Age at injury (years) 9.5 5.4 .2 - 16.6 
Time from TBI (years) 8.3 1.3 5.8 - 10.7 
Mod/Sev TBI     
Age at evaluation (years) 19.8 4.2 11.3 - 26.4 
Age at injury (years) 10.7 4.1 .4 - 16.8 
Time from TBI (years) 9.0 1.1 6.8 - 10.8 
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3.2 CLINICAL ASSESSMENT AND ANTHROPOMETRY 
The anthropometry of the three participant groups is shown in table 4. There was no 
statistical difference (independent samples Kruskal-Wallis test) between groups with 
regards to height, weight, BMI, skinfold thickness, abdominal circumference or body 
composition [Table 6]. 
 
N=72 Mild (n=24) Mod/Sev (n=31) Control (n=17) p 
Height (cm) 165.2 ± 14.1 172.3 ± 9.9 171.8 ± 14.0 p=.112 
Weight (kg) 66.1 ± 22.6 69.4 ± 12.1 72.2 ± 21.8 p=.655 
BMI 23.6 ± 6.1 23.3 ± 3.6 24.1 ± 5.3 p=.703 
Skinfold Biceps (mm) 7.2 ± 5.9 7.7 ± 7.1 7.2 ± 5.6 p=.955 
Skinfold Triceps (mm) 13.8 ± 9.2 13.5 ± 12.0 13.8 ± 8.7 p=.497 
Body fat (%) 23 ± 12 20 ± 10 21 ± 7 p=.597 
Abdominal circumference (cm) 77.0 ± 12.9 79.0 ± 8.1 80.5 ± 12.2 p=.753 
 
Table 6 Auxology of participant groups 
 
Comparison of SD scores did not show any statistical difference between groups either 
(independent samples Kruskal Wallis test) [ Table 7 ]. 
 
N=72 Mild (n=24) Mod/Sev (n=31) Control (n=17) p 
Height SDS 
(range) 
0.185 ± 1.17 
(-2.0 – 2.43) 
0.234 ± 0.92 
(-1.74 – 2.45) 
0.439 ± 0.92 




0.775 ± 1.49 
(-2.56 – 3.88) 
0.636 ± 1.02 
(-1.36 – 2.85) 
1.095 ± 1.03 




0.732 ± 1.29 
(-1.81 – 3.17) 
0.528 ± 0.95 
(-1.08 – 2.81) 
0.953 ± 1.14 
(-0.65 – 3.44) 
p=.554 
 





3.3 ENDOCRINE RESULTS 
3.3.1 Baseline endocrine function 
All participants were clinically euthyroid and had normal thyroid and posterior pituitary 
function. Testosterone levels in pubertal/post-pubertal males were within the normal 
range [Table 8]. 
One post pubertal female with primary amenorrhea and history of eating disorder 3 
years ago had low levels of both oestradiol (<50 pmol/L) and gonadotropins. IGF1 SDS 
and IGF-BP3 SDS for this participant were -2.39 and -2.14 respectively. 
 
N=25 Mean Minimum Maximum 
Reference 
range 
TSH (mIU/L) (n=25) 2.6 0.6 4.9 0.5-5 
FT4 (pmol/L) (n=25) 15.8 11.5 20.2 9-20 
Testosterone (nmol/L) (n=15) 18.5 9.3 28.1 9-30 
Oestradiol (pmol/L) (n=10) 194.1 50.0 572.0 >73 
IGF1 (nmol/L) (n=23) 37.5 21.6 60.1 Age dependent 
IGF-BP3 (mg/L) (n=23) 3.2 2.3 4.6 Age dependent 
IGF1 (SDS) -0.56 -2.39 1.53 Age dependent 
IGF1BP3 (SDS) -0.58 -2.14 1.13 Age dependent 
 
Table 8 Baseline endocrine function in mod/sev TBI participants 
 
3.3.2 Stimulated growth hormone and cortisol 
Twenty-five out of 31 mod/sev TBI participants had a stimulation test. In 7/25 (4 male 
and 3 female including the one with secondary amenorrhea and low gonadotropin 
levels), GH response to ITT using age/pubertal stage appropriate cut-off values was 



























1 F 12 3 1.42 2.58 Mod Fall 4.4 0.21 1.13 524 
2 M 22 5 1.10 1.30 Mod Pedestrian 1.8 -0.49 -0.86 586 
3 F 16 4 0.76 0.16 Mod Pedestrian 3.7 -2.39 -2.14 584 
4 M 24 5 0.23 -1.04 Sev Fall 0.1 -0.46 -0.74 501 
5 M 25 5 -0.33 0.59 Mod Pedestrian 0.1 -0.30 -0.51 526 
6 M 14 3 0.35 -0.36 Mod Cyclist 1.2 -1.06 -1.17 483 
7 F 17 5 0.35 0.73 Sev Pedestrian 4.1 -0.71 0.76 511 
 
Table 9 Mod/sev TBI participants with abnormal GH response following ITT 
 
IGF1 SDS was not different between participants with normal and abnormal stimulated 
GH response (Mann-Whitney p=.86) [Figure 13]. The peak GH response to ITT did not 
correlate with IGF1 (ρ = .21, p =.35), IGF-BP3 (ρ = -.04, p =.87), IGF1 SDS (ρ = .07, p 
=.77) or IGF-BP3 SDS (ρ =-.06, p =.79) even when controlling for weight. 
 
Figure 13 IGF1 SDS in TBI patients depending on result of GH stimulation test 
 
In three ITT’s, intravenous glucose had to be administered to correct symptomatic 
hypoglycaemia that did not respond to oral treatment. 
In two participants, the cortisol response was suboptimal (peak cortisol 392 and 
483nmol/l). One of them had also abnormal stimulated GH response (peak GH 1.2 
mcg/L) but normal height for his age (Height SDS 0.35). 
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3.3.3 Spontaneous growth hormone and cortisol 
Twenty-two of 31 participants completed an overnight GH profile (eight did not consent 
to the overnight stay and one GH profile was incomplete due to difficult venous 
access). 
3.3.3.1 Growth hormone 
The following pulsatility parameters of GH were studied: half-life, area under the curve, 
mean secretion, peak secretion, number of secretory peaks, mean secretion pulse 
amplitude, mean secretion pulse mass and approximate entropy (ApEn). 
Mean 12-hour GH secretion was under 3.3 mcg/l in 18/22, under 2 mcg/l in 12/22 and 
under 1 mcg/l in 4/22 profiles. In the four participants with mean 12-hour GH secretion 
<1 mcg/l (“x” in Figure 14 ), peak stimulated GH was 9.7, 4.4, 3.7 and 0.1 mcg/l (two 
abnormal ITT’s using age appropriate cut-offs). There was no significant correlation 
between peak stimulated and peak spontaneous GH levels (ρ=.17, p=0.45). Although 
spontaneous peak GH was higher compared to the stimulated one (11.1±7 vs 8.1±6.9 




Figure 14 Peak stimulated and spontaneous overnight GH secretion in survivors of childhood mod/sev 
TBI. 
 
Agreement between spontaneous (“normal”/”abnormal” profile using cut-off of 
<1mcg/L, <2mcg/L or <3.3<mcg/L) and “normal”/”abnormal” stimulated GH secretion 
(ITT) was less than .20 in all comparisons. This indicates poor agreement. 
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Using the GH cut-off from the stimulation test as the differentiating factor to categorise 
a profile as “normal” or “abnormal” [84], only one profile was “abnormal”. In this 
participant, both stimulated (3.7 mcg/L) and spontaneous peak GH secretion 
(2.7mcg/L) were low. This 16y old (TBI at 7y of age) female participant had also low 
IGF1 (-2.39 SD), but normal height (0.76 SD), weight (0.39 SD) and did not have any 
symptoms of fatigue. 












Figure 15 Individual overnight GH profiles of children/young adults with TBI (black square at the top right 
corner indicates patients with abnormal ITT). X axis: time 12 hours (8pm to 8am), Y axis: GH (mcg/L) 
 
Characteristics of GH profiles after deconvolution analysis in mod/sev TBI participants 




 Mean ± SD Minimum Maximum *Mean ± SD 
GH Basal Secretion (mcg/L/min) 0.0051 ± 0.0048 0.0002 0.0182 0.0011± 0.0003 
GH Half-life (min) 20.21 ± 5.32 11.5 29.5 19.32± 0.57 
GH AUC (mcg/L/min) 1600 ± 978 367 4585 1064.3± 147.2 
GH Average (mcg/L) 2.22 ± 1.35 0.52 6.37 0.87± 0.12 
GH Max Measured (mcg/L) 11.2 ± 7.0 2.7 37.6 3.11± 0.4 
GH Secretory Peaks 8 ± 2 3 14 5.5± 0.3 
GH Mean Secretory Pulse Height 0.39 ± 0.30 0.12 1.39 0.17± 0.03 
GH Mean Secretion Pulse Mass 6.98 ± 5.06 1.80 24.68 4.39± 0.69 
GH ApEn 0.51 ± 0.23 0.18 0.87   
 
Table 10 Parameters of GH profiles in mod/sev TBI patient using deconvolution tools (AutoDecon) and 
representative values from *Nindl et al [249] (Cluster) 
 
Average GH secretion correlated negatively with age in our relatively age-homogenous 
study group (ρ=-.516, p=0.007) [Figure 16]. 
 
Figure 16 Average overnight GH secretion in mod/sev TBI group 
 
In contrast to stimulated GH levels, which did not correlate with IGF1/IGF-BP3 and 
their standard deviation scores (SDS), parameters of spontaneous GH secretion 
(average, maximum, mean secretion pulse mass) correlated with IGF1/IGF-BP3 
[Figure 17]. 
SDS for IGF1/IGF-BP3, also correlated with basal GH secretion and mean secretory 
pulse height (r=.495, p=.022 and r=.535, p=.013 respectively) but not with other 





Figure 17 Correlation between IGF1 and measures of spontaneous GH secretion 
 
Participants with average overnight GH secretion <1mcg/L had significantly lower IGF1 









Mean, overnight, 12-hour cortisol concentration was 170 nmol/l and the mean of peak 
overnight levels 540 nmol/L. Cortisol levels from 00:00-02:00 were significantly lower 
than those between 06:00-08:00 (paired samples t-test, p<.001) [Table 11] and [Figure 
19]. 
 Mean SD Minimum Maximum 
Maximum overnight cortisol (nmol/L) 540 127 227 811 
Mean overnight cortisol (nmol/L) 170 63 33 310 
Mean cortisol 00:00 – 02:00 (nmol/L) 59 35 13 127 
Mean cortisol 06:00 – 08:00 (nmol/L) 411 136 132 715 
 
Table 11 Summary data of overnight cortisol secretion in mod/sev TBI patients 
 
 
Figure 19 Midnight and morning plasma cortisol levels in mod/sev TBI patients 
 
Maximum measured cortisol was under 500 nmol/l in 9/22 profiles. Stimulated cortisol 
(ITT) was normal in seven of these. In one of the two participants with abnormal 
stimulated and spontaneous cortisol secretion, GH response to ITT was also abnormal 
(peak GH 1.2 mcg/L). In the other participant (20y female), stimulated GH response 
was normal (peak GH 6.2 mcg/L) but ApEn for cortisol was very low (0.009, Z score -
3.15) as was the average cortisol secretion which was the lowest in the study group 
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(minimum values in Table 11 are all from this participant). Fatigue and depression 
scores in this participant were high. 
Peak spontaneous and stimulated cortisol levels correlated strongly (r=.788, p<.001) 
[Figure 20]. 
 
Figure 20 Stimulated and spontaneous plasma cortisol in mod/sev TBI patients 
 
The correlation between stimulated and measures of spontaneous cortisol secretion 
was also significant for 00:00-02:00 am cortisol (r=.675, p<.001), 06:00-08:00 cortisol 
(r=.677, p<.001) and mean overnight cortisol secretion (r=.746, p<.001). The 
correlation with pulse height, pulse mass and basal secretion was not significant. 
The average number of cortisol secretory episodes was 7 (range 2-9) and almost all 
occurred in the second half of the 12-hour overnight profile [Table 12 and Figure 21]. 
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COR Basal Secretion (nmol/L) 0.50 ± 0.42 
COR Half-life (min) 58.1 ± 22.0 
COR AUC (nmol/L) 122562 ± 45685 
COR Average (nmol/L) 170 ± 63 
COR Max Measured (nmol/L) 539 ± 127 
COR Peaks 7 ± 2 
COR Mean Secretory Pulse Height (nmol/L) 23.3 ± 18.1 
COR Mean Secretion Pulse Mass (nmol/L) 251.5 ± 112.7 
COR ApEn 0.45 ± 0.14 
 















Figure 21 Individual overnight cortisol profiles of children/young adults with mod/sev TBI. X axis: time 
(minutes), Y axis: cortisol (nmol/L) 
 
3.3.4 Salivary cortisol 
Salivary cortisol and cortisone levels were averaged for each of the five samples 
collected over three days. CAR was calculated for each one of three sampling days 
(before Dexamethasone suppression). Participants with negative CAR were excluded 
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only if CAR was negative on all three sampling days. Complete absence of a post-
awakening increase is likely to occur only if the delay and initiation of sampling is long 
enough so the first cortisol level exceeds the peak of the underlying CAR but can rarely 
be seen in patients with brain lesions (particularly in the hippocampus) [254]. A 
negative CAR over all three sampling days occurred in two participants (one control 
and one mild TBI). 
Two way mixed ANOVA for the CAR over three consecutive sampling days did not 
demonstrate an effect of TBI [F(1,39)=22.25, p=.445], depression [F(1,39)=.002, 
p=.963] or fatigue [F(1,39)=.058, p=.811] on CAR over time. 
When comparing the average CAR over three days there was no difference between 
groups (Kruskal-Wallis independent samples test, p=.053) [Figure 19] or when 
comparing TBI vs controls (Mann-Whitney U test, p=.828) [Figure 20].  
Analyses were done excluding the two participants having a negative CAR over three 
days. Results were not different when those were included in the analysis. 
 
 
      n=10        n=17      n=23 





    n=10             n=40 
Figure 23 Comparison of Cortisol Awakening Response between TBI and non-TBI/control group 
 
Subgroup analysis did not show any difference in CAR between male and female 
participants (Kruskal-Wallis independent samples test, p=.848) or between participants 
with fatigue (Mann-Whitney U test, p=.110) or depression (Mann-Whitney U test, 
p=.138). 
Descriptive statistics of salivary cortisone samples before suppression with 
Dexamethasone are shown in Table 13. ANOVA with Bonferroni adjustment for each 










Control 16.3 6.2 
.083 Mild 19.8 4.4 
Mod/Sev 22.0 8.0 
30min post waking 
Control 18.7 8.6 
.083 Mild 25.4 7.2 
Mod/Sev 23.9 7.2 
4-5h post waking 
Control 9.0 4.5 
.178 Mild 12.1 5.0 
Mod/Sev 12.6 5.5 
8-10h post waking 
Control 8.4 2.6 
.541 Mild 6.8 4.2 
Mod/Sev 7.8 4.0 
Bedtime 
Control 2.5 2.0 
.628 Mild 3.0 1.8 
Mod/Sev 3.4 2.8 
 
Table 13 Salivary cortisone levels in TBI and control groups. Values represent the average over 3 days of 
consecutive sampling. 
 
Circadian rhythm pattern was preserved in all three groups (mild, mod/sev TBI and 
control). The change over time in salivary cortisone levels between groups was 
statistically significant [F(2,47)=3.23, p=.049, partial ƞ2=.121] due to the cortisone 
difference drop (but not absolute levels) between mild TBI and control group from 4-5h 








Figure 25 Salivary cortisone difference between 4-5h and 8-10h post waking in TBI and control groups.  
 
There was no difference between groups in cortisone suppression with 
dexamethasone [F(2,46)=1.85, p=.169] [Figure 26]. In two participants (one mild and 
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one mod/sev TBI) there was no suppression of morning salivary cortisone. Both had 
normal auxology and no depressive symptomatology. 
 
 
Figure 26 Difference in morning salivary cortisone pre- and post- suppression with Dexamethasone in TBI 
and control groups.  
 
3.3.5 Endocrine results summary 
Baseline endocrine function was normal in all but one female participant with primary 
amenorrhea. There was no clinical or biochemical indication of posterior pituitary 
dysfunction. GH response to standard stimulation testing (ITT) was abnormal in almost 
one third of mod/sev TBI participants. This did not correlate with IGF1/IGF-BP3 or 
auxology. Cortisol response to the same test was suboptimal in 10% of participants. 
Spontaneous and stimulated GH levels did not correlate. In one participant, both 
stimulated and spontaneous peak GH secretion was low. Mean 12-hour GH secretion 
was low (under 1 mcg/l) in 20% of overnight profiles. Measures of spontaneous GH 
secretion (basal, average, maximum, mean secretion pulse mass) correlated with 
IGF1/IGF-BP3. 
Spontaneous cortisol was under 500 nmol/l in 9/22 overnight profiles tests. Stimulated 
cortisol was normal in 7 of these. Spontaneous and stimulated cortisol correlated 
strongly. Cortisol pulsatility was preserved in all participants. 
Salivary cortisol sample analysis did not show any clinically significant difference 
between groups in regards to CAR or suppression with dexamethasone. Circadian 
rhythm patterns were preserved overall with only a slightly more pronounced drop in 
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cortisone levels (between 4-5h and 8-10h post waking) in mild TBI participants when 




3.4 NEUROPSYCHOLOGY RESULTS 
3.4.1 Cognitive results 
IQ scores were not different between groups (Kruskal-Wallis independent samples 
test, p=.068) [Figure 27] or when comparing TBI vs non-TBI (control) groups (Mann-
Whitney U test, p=.200) 
 
 n=17 n=24 n=30 
Figure 27 Comparison of summary IQ scores between TBI and control groups 
 
Verbal IQ (VIQ) percentiles were lower in the Mod/Sev TBI group (39±33 centile) when 
compared to the control (62±25 centile) and mild TBI group (60±23 centile) (Kruskal-
Wallis independent samples test, p=.029 and .022 respectively) [Figure 28]. There was 





n=17     n=24     n=30 
Figure 28 Comparison of Verbal IQ between TBI and control groups 
 
Performance IQ (PIQ) percentiles between groups was not statistically significant 
(Kruskal-Wallis independent samples test, p=.415) [Figure 29] or when comparing TBI 
vs non-TBI (control) groups (Mann-Whitney U test, p=.304) [Figure 30]. 
 
  n=17         n=24      n=30 





n=17           n=54 




3.4.2 Psychology and Behaviour results 
3.4.2.1 Behaviour checklist and self-report 
The Self-Report (children CSR, adult ASR) and Behaviour Checklist (children CBCL, 
adult ABCL) is designed to obtain own and proxy reports of competencies and 
problems in a standardised format. As what individuals and especially adolescents 
report about themselves is subject to their recall at that moment, candour and self-
awareness, reports by other informants (multiaxial assessment approach) were also 
analysed and compared. 
 Total competency T scores were different between groups (Kruskal-Wallis 
independent samples test, p=.042). Pairwise comparisons showed a significant 
difference between mod/sev TBI and the control group [Figure 31]. T scores above 70 
are in the clinical range. 
 
n=17    n=24     n=30 
 
Figure 31 Comparison of Total Competency scores between TBI and control groups (self-report) 
 
The same was seen with proxy reporting (Kruskal-Wallis independent samples test, 




n=17    n=24    n=30 
 
Figure 32 Comparison of Total Competency scores between TBI and control groups (proxy-report) 
 
3.4.2.1.1 Externalising behaviour 
Externalising grouping consists of behaviour syndromes that mainly involve conflict 
with other people and with social mores. 
There were differences between groups (Kruskal-Wallis independent samples test, 
p=.006) with the mod/sev TBI group having higher T scores. There was no statistical 
difference between the mild TBI and control group [Figure 33]. 
The same difference was observed with proxy assessment (Kruskal-Wallis 





n=17    n=24    n=30 
 
Figure 33 Comparison of Externalising behaviour between TBI and control groups (self-report) 
 
 
n=17    n=24    n=30 
 




When analysing the components contributing to externalising behaviour problems, the 
mod/sev TBI group had higher T scores for aggressive behaviour (Kruskal-Wallis 
independent samples test, p=.003) [Figure 35] compared to the control group. 
 
n=17         n=24            n=30 
 
 
Figure 35 Comparison of Aggressive behaviour between TBI and control groups (self-report) 
 
Proxy T scores for aggressive behaviour were also different between groups (Kruskal-





    n=17         n=24        n=30 
 
Figure 36 Comparison of Aggressive behaviour between TBI and control groups (proxy-report) 
 
T scores were also higher in the mod/sev TBI group in regards to rule breaking 




       n=17            n=24          n=30 
 
Figure 37 Comparison of Rule breaking behaviour between TBI and control groups (self-report) 
 
A similar pattern was seen with proxy assessment (Kruskal-Wallis independent 
samples test, p=.004) [Figure 38] with the mod/sev TBI group having significantly 





       n=17        n=24            n=30 
 
Figure 38 Comparison of Rule breaking behaviour between TBI and control groups (proxy-report) 
 
The Thought problems scale is mainly comprised of low prevalence items and has low 
internal consistency unless sample sizes are large. It measures symptoms common in 
several mental disorders (hallucinations, OCD-symptoms, self-harm and suicide 
attempts). 
Self-reporting showed differences between groups (Kruskal-Wallis independent 
samples test, p=.008) [Figure 39] with T scores for the mod/sev TBI group being higher 
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Figure 39 Comparison of Thought problems between TBI and control groups (self-report) 
 
Proxy assessment did not demonstrate a difference between groups (Kruskal-Wallis 
independent samples test, p=.079) [Figure 40]. 
 
n=17            n=24        n=30 
Figure 40 Comparison of Thought problems between TBI and control groups (proxy-report) 
 
In the Attention problems scale mod/sev TBI participants demonstrated higher T 
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Figure 41 Comparison of Attention problems between TBI and control groups (self-report) 
 
Proxy scores were similar with the mod/sev TBI group demonstrating higher T scores 
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Figure 42 Comparison of Attention problems between TBI and control groups (proxy-report) 
 
3.4.2.1.2 Internalising behaviour 
The Internalising grouping consists of three syndromes (anxious/depressed, 
withdrawal, somatic complains) that are mainly within the self. 
There were differences between groups (Kruskal-Wallis independent samples test, 
p=.046) [Figure 43] with Internalizing T scores being higher in the mod/sev TBI group 
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Figure 43 Comparison of Internalising problems between TBI and control groups (self-report) 
 
Proxy assessment did not demonstrate differences between groups (Kruskal-Wallis 
independent samples test, p=.069) [Figure 44]. 
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Anxiety/depression and somatic problems T scores were not different between groups 
with either self or proxy assessment (Kruskal-Wallis independent samples test, p> .1) 
[Figure 45] & [Figure 46]. 
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Figure 46 Comparison of Somatic problems between TBI and control groups (self and proxy-report) 
 
Analysis of ASEBA derived DSM-oriented scales were also consistent with most of the 
ASEBA total and sub score results. 
Correlation between self and proxy reports for ASEBA summary [Figure 47], 
externalising and internalising [Figure 48], anxiety/depression [Figure 49], withdrawal 
[Figure 50], somatic symptoms [Figure 51], attention [Figure 52 ] and aggressive 





Figure 47 Correlation between self and proxy ASEBA Summary T scores 
 
 




























Figure 54 Correlation between self and proxy ASEBA Rule breaking behaviour T scores 
 
3.4.2.2 Depression and Anxiety 
In addition to ASEBA-derived DSM-oriented scales for behaviour and anxiety, 
assessments for depression and anxiety were also undertaken using specific clinical 
instruments. Beck Depression Inventory (BDI) was used for participants 13 years of 




   n=10    n=14    n=28 
 
Figure 55 Comparison of Depression scores (BDI) in TBI and control groups 
 
Depression scores using BDI were significantly higher in the mod/sev TBI group when 
compared to the control group (Kruskal-Wallis independent samples test, p=.011) 
[Figure 55]. Almost a third (9/28) of mod/sev TBI participants had a score of 17 or 
above which is seen only in patients with clinical depression. A similar proportion (5/18) 
of mild TBI participants scored above 17. 
No differences were demonstrated between groups in the smaller group of younger 
participants (n=9) who were assessed using the Birleson depression scale. 
Measures of spontaneous or stimulated GH or cortisol secretion were not different in 
participants with depression compared to the ones without. 
Anxiety assessment using the Beck Anxiety Inventory (BAI) did not demonstrate any 
differences between groups (Kruskal-Wallis independent samples test, p=.798) [Figure 
56]. Only one participant in the mild TBI group had anxiety levels in the severe range 




n=11     n=15       n=28 
Figure 56 Comparison of Anxiety scores (BAI) in TBI and control groups 
 
3.4.2.3 BRIEF (Behaviour Rating Inventory of Executive Function) 
Global BRIEF scores were not different between groups (Kruskal-Wallis independent 
samples test, p=.207) [Figure 57]. 
 
   n=11       n=15     n=26 
Figure 57 Comparison of Global T scores between TBI and control groups (BRIEF) 
 
Behavioural regulation T scores were higher in mod/sev TBI group and statistically 
significant when compared to the control group (Kruskal-Wallis independent samples 
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Figure 58 Comparison of Behavioural Regulation T scores between TBI and control groups (BRIEF) 
 
When reviewing the clinical scales assessed with Behavioural Regulation, the main 
difference between groups was in the inhibition scale (impulsivity) (Kruskal-Wallis 
independent samples test, p=.009) [while there were no differences in the other two 
scales (shift and emotional control) [Figure 59]. 
 




n=11      n=15    n=26 
Figure 59 Comparison of Inhibition T scores between TBI and control groups (BRIEF) 
 
Metacognition summary T score was not different between groups (Kruskal-Wallis 
independent samples test, p=.315) [Figure 60]. 
 
n=11         n=15     n=26 
Figure 60 Comparison of Metacognition T scores between TBI and control groups (BRIEF) 
 
Analysis of scales assessed in Metacognition (i.e. initiation, working memory, 
organisation of materials and monitor) were not different between groups except for 
working memory T scores. These were higher in the mod/sev TBI group suggesting a 
higher level of dysfunction in this domain, which involves holding information in mind 





n=11       n=15    n=26 
 Figure 61 Comparison of Working memory T scores between TBI and control groups (BRIEF) 
 
3.4.3 Neuropsychology results summary 
Cognitive impairment was seen in the mod/sev TBI group. Verbal IQ was lower (-20% 
when compared to the control or mild TBI group) as was working memory which is 
important for holding information in mind in order to completing a task. The same group 
had higher scores for aggressive/rule breaking behaviour, attention problems, 




3.5 QUALITY OF LIFE AND FATIGUE RESULTS 
3.5.1 PedsQL 
Total PedsQL score was not different between groups (Kruskal-Wallis independent 
samples test, p=.265) [Figure 62]. 
 
n=14       n=20         n=30 
Figure 62 Comparison of Total QoL scores between TBI and control groups (PedsQL) 
 
When comparing two groups (TBI vs non-TBI), the total PedsQL score in the TBI group 
was lower (80.3±16.8 vs 88.3±7.9, 95% confidence interval of the difference 1.5-14.4). 
The difference was statistically significant (t-test for unequal variances, p=.016) [Figure 
63]. 
 




Figure 63 Comparison of Total QoL scores between TBI and non-TBI groups (PedsQL) 
 
Physical and Psychosocial sub-scores were not significantly different between the 
three groups (Kruskal-Wallis independent samples test, p=.716 and p=.127 
respectively) [Figure 64]. 
 
n=14      n=20        n=30 
 
n=14       n=20    n=30 
Figure 64 Comparison of Physical and Psychosocial QoL scores between TBI and control groups 
(PedsQL) 
 
When comparing two groups (TBI vs non-TBI), the Psychosocial PedsQL score in the 
TBI group was lower by (76.6±19.1 vs 87.5±8.6, 95% confidence interval of difference 
3.7-18.0). The difference was statistically significant (t-test for unequal variances, 




         n=50              n=14 
Figure 65 Comparison of Psychosocial QoL scores between TBI and non-TBI groups (PedsQL) 
 
The school sub-score was not significantly different between the three groups (Kruskal-
Wallis independent samples test, p=.154), but when comparing two groups (TBI vs 
non-TBI) it was lower in the TBI group (74.8±20 vs 84.4±9.3, 95% confidence interval 
of the difference 3.9-19.3). The difference was statistically significant (t-test for unequal 
variances, p=.004) [Figure 66].  
 
n=50              n=14 
Figure 66 Comparison of School QoL sub-scores between TBI and non-TBI groups (PedsQL) 
 
There was a strong correlation between self and proxy reports [Table 14]. 
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 Pearson r p 
PedsQL Total score .665 <.001 
PedsQL Physical score .555 <.001 
PedsQL Psychosocial .540 <.001 
PedsQL Feelings .655 <.001 
PedsQL Social .569 <.001 
PedsQL School .625 <.001 
Table 14 Correlation between self and proxy report for PedsQL. 
 
Overall, sixteen participants (7 mild, 9 mod/sev TBI) had a summary PedsQL score of 
less than 69.7%, which is the level for detecting children with chronic health conditions. 
Physical and psychosocial health summary sub-scores were less than 69.7% in 5 and 
9 participants respectively. 
3.5.2 Health utilities index (HUI) 
Mean HUI scores were not significantly different between the three groups with either 
self or proxy report (Kruskal-Wallis independent samples test, p=.099 and .088 




n=17       n=23       n=30 
 
n=17       n=23       n=30 
Figure 67 Comparison of HUI scores between TBI and control groups (self and proxy report) 
 
Two group comparison (TBI vs non-TBI) showed that the mean HUI score in the TBI 
group was significantly lower in the control group [0.765 ± 0.28 vs 0.922 ± 0.09 (t-test 
for unequal variances, p=.001) with self-assessment and 0.706 ± 0.34 vs 0.942± 0.06 
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n=17         n=53 
Figure 68 Comparison of HUI scores between TBI and non-TBI groups (self and proxy report) 
 
Analysis of single attribute scores did not show any differences for Vision, Speech, 
Ambulation, Dexterity and Pain between groups with either self- or proxy- assessment. 
Cognition attribute scores were significantly lower in the TBI group (Kruskal-Wallis 
independent samples test, p=.006) for both mild TBI and mod/sev TBI groups 
compared to the control group [Figure 69]. 
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Cognition attribute scores were also lower with proxy-assessment (Kruskal-Wallis 
independent samples test, p=.004) but only between the mod/sev TBI and control 
group [Figure 70]. 
 
    n=17       n=23      n=30 
Figure 70 Comparison of HUI Cognition scores between TBI and non-TBI groups (proxy report) 
 
Emotion attribute scores were not significantly different with self-assessment but were 
lower in the mod/sev TBI vs control group with proxy assessment (Kruskal-Wallis 
independent samples test, p=.016) [Figure 71]. 
 
 
    n=17      n=23    n=30 
Figure 71 Comparison of HUI Emotion scores between TBI and non-TBI groups (proxy report) 
 
With two group comparison (TBI vs non-TBI), emotion attribute scores were 
significantly lower with both self [0.920 ± 0.217 vs 0.995 ± 0.022 (t-test for unequal 
variances, p=.017] and proxy assessment [0.885 ± 0.24 vs 0.992 ± 0.025 (t-test for 
unequal variances, p=.007]. 
3.5.3 Participation (Child and Adolescent Scale of Participation- [CASP]) 
Participation scores were lower in the mod/sev TBI group as seen in Table 15. The 
difference between the three groups was not statistically significant (Kruskal-Wallis 
independent samples test, p=.082). 
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 Mean SD 
95% Confidence Interval 
for Mean 
Mild 95.5 6.5 91.9 - 99.1 
Mod/Sev 89.6 12.7 83.2 - 95.9 
Control 99.1 1.6 97.7 - 100 
Table 15 CASP scores in mild, mod/sev TBI and control groups 
 
Two group comparison (TBI vs non-TBI) showed that the mean CASP score in the TBI 
group was significantly lower, 92.3 ± 10.6 vs 99.1 ± 1.6 (t-test for unequal variances, 
p=.001) [Figure 72]. 
 
 
 n=33         n=8 
Figure 72 Comparison of CASP scores between TBI and non-TBI groups. 
 
3.5.4 Fatigue 
Fatigues scores as assessed with the Chalder fatigue scale are shown in Table 16. 
When comparing two groups (TBI vs non-TBI/control) the difference was statistically 
significant (t-test for unequal variances) using either bimodal or Likert scoring method. 
TBI participants had higher fatigue scores. 
 Groups Mean SD p 
CFS Bimodal (0-11) 
Control .43 .852 
<.001 
TBI 3.13 3.462 
CFS Likert (0-33) 
Control 10.07 3.362 
.035 
TBI 13.07 7.129 




Fatigue scores were significantly different between the 3 groups using bimodal scoring 
(scale 0-11) (Kruskal-Wallis independent samples test, p=.02) but not when using 
Likert scores (Kruskal-Wallis independent samples test, p=.339) [Figure 73]. 
 
 
    n=14      n=18    n=28 
 
Figure 73 Comparison of Fatigue scores between TBI and control groups 
 
As the binomial fatigue score for the control group was .43 ± .85 (mean±SD) a bimodal 
score of ≥3 (same as the bimodal score initially recommended for identifying significant 
fatigue [239]) or ≥16 (Likert) was considered abnormal for our study sample and 
suggestive of fatigue levels above what would be expected in healthy controls. 
20/46 of TBI participants had fatigue scores of 3 or above (mod/sev 13/28, mild 7/18) 
and 1/14 in the control group. The difference was statistically significant (Chi-Square, 
p=.013) [Figure 74]. 
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Five participants (4 mod/sev and 1 mild TBI) had bimodal fatigue scores above 9, 
which is seen in Chronic Fatigue Syndrome (CFS) sufferers (mean 9.14 and SD 2.73 
from large study involving 361 CFS sufferers and 1615 healthy individuals from the 
community [285]) 
There were more females with fatigue (8/20 vs 13/40 males) but the difference in 
fatigue between TBI and non-TBI females was not significant (Fisher’s exact test, 
p=.656). The difference was significant in males as 13/29 in the TBI and 0/11 in the 
control group reported fatigue (Fisher’s exact test, p=.006). 
Fatigue scores correlated negatively with PedsQL scores (ρ= -.68, p<0.001). 
Participants with higher levels of fatigue tend to have poorer QoL (physical and 
psychosocial) (Mann-Whitney U, p<.001) [Figure 75]. 
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Fatigue was also associated with higher Anxiety and Depression levels (Mann-Whitney 
U, p=.003 and <.001 respectively) [Figure 76]. 
 
 
        n=39         n=21            n=39          n=21 
Fatigue              Fatigue 
 
Figure 76 Association between anxiety scores (BAI), depression scores (BDI) and fatigue. 
 
3.5.5 HRQL and fatigue results summary 
Measures of HRQL associated with physical health (vision, speech, ambulation, 
dexterity) were not different between groups. Psychosocial measures of HRQL, 
although not statistically different when comparing the three groups (mid, mod/sev, 
controls) were lower when comparing all TBI participants (mild/mod/sev) to the non-
TBI/control group. Cognition scores as assessed with the Health Utilities Index (HUI) 
were lower in the mod/sev TBI group. Cognition, emotion and participation (CASP) 
scores were different with two-group comparison (lower in TBI vs non-TBI). Self and 
proxy reports correlated strongly. 
3.5.5.1 HRQL, fatigue and endocrine status summary 
There was no significant difference in quality of life (PedsQL) or any of the various 
health attribute scores (HUI) between mod/sev TBI participants with normal and 
abnormal stimulated GH secretion. 
Fatigue (using binomial or Likert score cut-offs) did not correlate with stimulated GH 
(Fisher exact Test, p=.208) [Figure 77] or cortisol status (Fisher exact Test, p=.739) as 




Figure 77 Fatigue (as assessed with Chandler fatigue scale) and GH status (as assessed with ITT) in 
mod/sev paediatric TBI survivors. 
 
Measures of spontaneous GH secretion (mean secretion pulse height) were 




n=10       n=12 
   Fatigue 
 
Figure 78 Fatigue and GH secretion pulse height in mod/sev TBI survivors 
 
Measures of spontaneous cortisol secretion (overnight cortisol profile) were not 
different between mod/sev TBI participants with or without fatigue. 
No difference was seen in CAR (Mann-Whitney U test, p=.414), or response to 
dexamethasone suppression (Mann-Whitney U test, p=.243) between the fatigue 
groups. The only significant difference was observed with bedtime salivary cortisone 
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3.6 NEUROIMAGING RESULTS 
Following screening, 56/72 participants (14 controls, 21 mild TBI, 21 mod/sev TBI) 
without any metallic implants or any other contraindication had a head MRI scan (10 
from the mod/sev TBI, 3 from the mild TBI and 3 from the control group were 
excluded). 
From the 42 TBI participants who had an MRI scan 19 were abnormal (4 in mild and 15 
in mod/sev TBI). Reported abnormalities included contusions in 15, white matter 
sheering injury in 1, frontal lobe cavities in 1, reduced brain volume in 1 and acoustic 
neuroma in 1 (incidental finding). Pituitary morphology (both anterior and posterior) 
was normal in all participants. 
Pituitary size as calculated with the ellipsoid formula was not different between groups 
when adjusting for pubertal stage (Kruskal-Wallis independent samples test, p=.309) 
[Figure 80]. 
 
   n=21      n=21    n=14 
Figure 80 Pituitary volume in mild, mod/sev TBI study participants and healthy controls 
 
Pituitary volume did not correlate with measures of spontaneous or stimulated GH or 
cortisol secretion. Pituitary volume was greater in participants with fatigue (Mann-
Whitney p=.039) but the difference was not significant when adjusting for pubertal 
stage (Mann-Whitney p=.285) as all participants with fatigue were at late stages or had 
completed puberty and as expected had larger pituitaries compared to younger 
participants. 
3.6.1 Voxel Based Morphometry (VBM) results 
VBM and ROI analysis for hippocampal areas demonstrated differences between the 
groups. 
Grey matter volume (GM) was overall different between groups [F(2,53)=8.59, p=.001]. 
When a Bonferroni adjustment was applied for multiple comparisons, GM volume in 
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the mod/sev TBI group remained significantly lower than the control group (756±83 vs 
874±84 ml) [Figure 81]. 
 
n=14        n=21    n=21 
Figure 81 Comparison of grey matter volume between TBI and control groups 
 
White matter volume (WMV) differences between groups did not reach statistical 
significance overall [F(2,53)=3.10, p=.053] so no further post hoc analyses were done. 
WMV in the mod/sev TBI group was 487±65ml vs 536±60ml in the control group. 
CSF volume was different between groups overall [F(2,53)=7.54, p=.001]. The only 
significant difference was between the mild and mod/sev TBI groups [Figure 82]. 
 
n=14           n=21        n=21 
Figure 82 Comparison of CSF volume between TBI and control groups 
 
Total intracranial volume (TIV) was lower in TBI participants (statistically significant 
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Figure 83 Comparison of Total Intracranial Volume between TBI and control groups 
 
Two-group comparisons (TBI vs non-TBI participants) demonstrated differences in 
GMV, WMV and TIV (t-test for unequal variances, p=.001, p=.015 and p=.008 
respectively) [Figure 84]. 
 
Figure 84 Comparison of Grey matter, White matter and Total Intracranial Volume between TBI (n=42) 




3.6.2 Region of Interest analysis 
Only hippocampal areas were explored with ROI analysis but data are available for 
analyses of other ROI. 
Left hippocampus volume was only just not statistically different between groups 
(Kruskal-Wallis independent samples test, p=.051) [Figure 85]. 
 
n=14        n=21    n=21 
Figure 85 Comparison of Left Hippocampus volume between TBI and control groups 
 
Right hippocampus volume was smaller in the mod/sev TBI group (Kruskal-Wallis 
independent samples test, p=.022). Pairwise comparisons showed the only significant 
difference being between the mod/sev TBI and control group [Figure 86]. 
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When comparing all TBI participants (mild/mod/sev as one group) vs the control group, 
significant differences were seen in all VBM - except for CSF- and hippocampus 
volumes. WM, GM, TIV and both hippocampus volumes were smaller in the TBI group 
[Table 17, Mann-Whitney test)]. 
 
 Control group TBI group p 
CSF volume (ml) 275± 31 284± 55 .718 
Grey matter volume (ml) 874± 84 781± 85 .002 
White matter volume (ml) 537± 60 490± 60 .032 
Total Intracranial Volume (ml) 1686± 140 1555± 158 .008 
Left hippocampus volume (ml) 5.16± .38 4.70± .55 .015 
Right hippocampus volume (ml) 5.24± .32 4.77± .56 .006 
Table 17 Comparison of brain (VBM analysis) and hippocampus volumes between TBI and control group. 
(mean±SD). 
 
When only participants that had completed their growth were included in the analysis 
(9 from control group, 35 TBI group), GM and right hippocampus volumes were still 
significantly smaller in the TBI group [Table 18, t-test adjusted for unequal variances 
when indicated]. 
 
 Control group TBI group p* 
CSF volume (ml) 282± 33 295± 52 .357 
Grey matter volume (ml) 839± 65 769 ±82 .022 
White matter volume (ml) 535± 59 496 ±61 .092 
Total Intracranial Volume (ml) 1657± 131 1560 ±162 .106 
Left hippocampus volume (ml) 5.08± .40 4.74 ±.58 .056 
Right hippocampus volume (ml) 5.20± .33 4.81 ±.58 .014 




4 CHAPTER 4 – (DISCUSSION) 
The KHINES study represents the first attempt to our knowledge to determine the long-
term prevalence of PTHP following TBI during childhood with detailed endocrine 
assessments of GH and cortisol including both spontaneous secretion analysis and 
provocation testing. KHINES also included assessments of cognitive function, fatigue, 
depression and quantification of quality of life and health status. Finally, detailed 
neuroimaging was undertaken in all participants including matched controls. 
KHINES succeeded in its aim to determine the long-term prevalence of PTHP following 
childhood TBI and support the limited number of previous paediatric TBI studies with 
sufficient patient numbers to recognise PTHP as a complication of paediatric TBI and 
estimate its prevalence [Table 19]. 
Although persistent endocrine dysfunction was identified only in a small number 
participants, KHINES raises questions regarding the use of dynamic testing for a 
condition where the a priori likelihood of pituitary/hypothalamic dysfunction is relatively 
small compared to high-risk populations where these tests have been traditionally used 
(i.e. oncology/neurosurgical patients with pituitary tumours, short children) and 
evaluates the use of spontaneous GH secretion and IGF1/BP3 as a diagnostic test for 
assessing pituitary function in TBI survivors. 
4.1 INTRODUCTION 
TBI remains a major cause of acquired neurological morbidity with an incidence of 100-
350 per 100,000 in the general population [300]. Studies estimate that 3.8% of the 
population will experience at least one hospital admission due to TBI by 35 years of 
age which highlights the scale of the problem [9]. Injury severity can vary from mild to 
severe with few fatal cases of TBI especially when associated with multiple other 
injuries/trauma. Causes of TBI differ depending on the age group with falls being more 
common in preschool age children while road traffic accidents are more common in the 
older 10-15 age group [7]. A similar pattern was seen in KHINES as in 40% of 
participants TBI was secondary to falls (including one possible non-accidental injury in 
an infant) and road traffic accidents in the remaining 60% (pedestrian or cyclist hit by a 
vehicle). Males are more at risk for TBI irrespective of age group [11] and the same 
was seen in KHINES. Although mild TBI is more common than more severe types of 
TBI, the percentage of participants with mild TBI in KHINES was lower compared to 
moderate/severe TBI participants (33% vs 43%). The same distribution was seen in 
the non-participant group (mild 25% vs moderate/severe TBI 33%) and it is therefore 
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Table 19 Paediatric TBI studies published to date (adapted from Casano-Sancho P. Arch Dis Child 2017) 
[307] 
unlikely that the higher representation of moderate/severe TBI participants in KHINES 
represents systematic error. It is possible this is simply a reflection of mild TBI patients 
being seen mostly in primary care rather in a hospital emergency department and 
therefore being less likely to be recruited to hospital based studies like KHINES. 
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4.2 TBI AND PTHP 
In the acute phase of TBI PTHP is a recognised complication which usually resolves 
spontaneously and is considered to represent physiological adaptation to critical illness 
[308, 309]. However, the natural history of acute PTHP and the risk factors determining 
the development of permanent PTHP remain an area or controversy. Our knowledge of 
chronic PTHP has evolved from single case reports, to case series, to an increasing 
number of studies using different inclusion criteria and methodology making their 
results difficult to compare. 
Spontaneous recovery from PTHP was initially described by Agha et al in a case report 
of a 25 year old male who was diagnosed with PTHP (GH and ACTH deficiency) 16 
months post TBI and showed full recovery at retesting after 5 years [310]. Tanriverdi et 
al in a pilot, prospective study reported that 3 years post TBI, pituitary function 
recovers in about half of mild and moderate TBI survivors but persists in those with 
severe TBI [311]. PTHP may therefore not be as persistent as initially described. 
Conversely, development of PTHP with isolated or multiple hormone deficiencies years 
after the acute TBI phase in patients where the initial endocrine assessment was 
normal has been described, but longer-term prospective data are not available to 
determine if these remain persistent [312, 313]. There is a possibility that these 
evolving and recovering hormonal deficiencies are just a reflection of inaccuracies and 
poor reproducibility of diagnostic testing as previously discussed in Chapter 1. 
The unclear natural history of TBI has impacted on the recommendations for assessing 
pituitary function following TBI which over the last decade have varied considerably. 
Some suggest that endocrine tests should be reserved only for survivors of moderate 
or severe TBI with risk factors including cerebral oedema with increased intracranial 
pressure, hypoxia/hypotension, diffuse axonal injury and basal skull fracture [20, 25, 
312, 314] while others recommend universal testing [306, 315]. Although the former 
approach can underestimate the true incidence of PTHP the latter approach carries the 
risk of over diagnosing PTHP if strict diagnostic criteria are not used. Identifying 
patients for endocrine screening on the basis of clinical symptoms is also difficult as 
the symptomatology of PTHP is non-specific and may overlap with TBI sequelae. 
Fatigue for example is very common amongst TBI patients without PTHP [152] but also 
in patients with GHD who show a good response with improved energy levels when 
treated with GH [162]. 
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The challenge therefore remains in deciding how, when and most importantly who to 
screen for PTHP considering that 3.8% of the population will experience at least one 
hospital admission due to TBI by 35 years of age. 
4.3 METHODS DISCUSSION 
Researchers have used various types of studies to explore the prevalence of PTHP 
following TBI in childhood. From the first case reports and case-control studies that led 
to the generation of the PTHP hypothesis there has been an exponential increase in 
the number of prospective studies in adults exploring risk factors and outcome 
measures of TBI. Similarly the first paediatric studies were retrospective with varied 
time intervals from TBI, inclusion criteria and methodology. Despite however the 
relatively flexible inclusion criteria most studies were not able to recruit high numbers 
of participants with some recruiting only 10-30% of eligible participants [Table 19]. 
Although KHINES followed the Kids’ Head Injury Study (prospective study of outcome 
in children with severe, moderate and mild TBI [KHIS, 2002-2004]) by nearly10 years, 
almost half (79/172) of contactable participants agreed to take part in KHINES which is 
comparable to recent prospective TBI studies. This was a result of their previous 
positive experience with KHIS and ensuring that the research psychologist who had 
been a member of the original KHIS team made the initial contact. In order to assess 
the potential of bias between participants that agreed to participate and those that 
didn’t, we compared these groups and we found no differences with regards to age, 
gender, time since TBI, severity of TBI, duration of post-traumatic amnesia, days in 
intensive case or type of structural abnormalities on acute neuroimaging 
(extradural/subdural haemorrhage, diffuse axonal injury or skull fracture). Although not 
statistically different, more participants with moderate/severe TBI, extradural 
haemorrhage and skull fracture agreed to take part in KHINES compared to non-
participants. 
TBI presents a new challenge to clinicians dealing with neuroendocrine conditions as 
the diagnosis of hypopituitarism is highly dependent on pre-analytical (confounders 
that are patient related such as age, BMI, gender, drugs, pre-existing medical 
conditions including mental health) and analytical factors. Previous studies have shown 
the prevalence of PTHP to vary greatly depending on inclusion criteria, testing 
methodology and analytical factors [38, 43, 47, 50, 316]. As outlined in Table 19 some 
researchers used only baseline endocrine tests while others employed dynamic tests 
in all or only in symptomatic participants. Only three paediatric TBI studies report 
assessing spontaneous GH secretion. 
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Even when applying the same inclusion criteria, sources or variation that affect the 
reported prevalence of PTHP cannot be ignored. Analytical factors such as changes in 
assays (mainly GH and cortisol which are the ones mostly measured with dynamic 
tests) can result in misclassification of a test result as abnormal. The use of new, 
automated, highly specific cortisol assays for example has resulted in a reduction of 
the cut-off used to diagnose adrenal insufficiency from 500 nmol/l to 420nmol/l [317]. 
For other hormones including GH and IGF1 consensus statements have been 
developed to standardise GH assays [318]. 
Assay changes however are only one of the sources of variation. Interpretation of 
dynamic tests relies on the use of specific cut-offs. For GH dynamic tests these cut-offs 
depend on the pharmacologic stimulus used but also on other confounders such as the 
age or BMI of the patient. Obesity blunts GH response to insulin [75], glucagon or 
GHRH+arginine [319] and therefore BMI specific cut-offs need to be applied. As these 
limitations/restrictions were not widely recognised previously, they may have resulted 
in over diagnosis of GHD in the past. In light of this, some researchers have 
reanalysed their data and subsequently reported a lower prevalence of PTHP [320]. All 
of the above apply for TBI studies that include assessment of spontaneous GH 
secretion with the addition of scarce normative data (most from studies using older 
non-standardised GH assays). 
Another source of overestimating the prevalence of PTHP is not including confirmatory 
retesting considering the intra-individual variation of GH dynamic tests [321-323]. It is 
possible that the intra-individual variation of GH dynamic tests is associated with the 
specific dynamic test protocol and sampling intervals. 
In the majority of paediatric TBI studies the somatotroph axis appears to be the one 
mostly affected, either in isolation or with other pituitary hormone deficiencies (thyroid, 
gonadotrophins) especially during the first year post TBI. It has been suggested that 
this is a result of the location of somatotroph and gonadotroph cells in the periphery of 
the anterior pituitary and fragility of the infundibular-hypothalamic-pituitary structure 
due to its unique anatomical and vascular structure [324]. In our study, only one female 
participant presented with hypogonadism, which was not isolated but combined with 
GHD. Thyroid function was normal in all participants. 
In view of the vulnerability of the somatotroph axis, the emphasis of the endocrine arm 
of KHINES was to assess the long term impact of TBI on GH status. Although various 
stimuli have been used for assessing GH status by stimulating pituitary GH release, 
KHINES chose the ITT as a) it is regarded to be the “gold standard” for assessing GH 
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status, b) it can assess both the somatotroph and HPA axes and c) the test is safe 
when done by experienced staff in a centre that already has extensive experience in 
performing the test. 
In contrast to GH stimulation tests where cut-offs for diagnosing GHD have been 
mostly agreed (in adults having an ITT, a GH cut-off of 3mcg/L has been accepted 
[76], while in children 7-10 mcg/L is being used in most centres), diagnostic criteria for 
defining “normal” spontaneous GH secretion are lacking. Some studies have used the 
presence of at least one GH concentration peak above the pharmacological test cut-off 
used for that age group as a criterion [84] while others have used mean overnight GH 
secretion instead, as this was found to have 100% specificity depending on the applied 
diagnostic cut-off (<1 mcg/L) [87, 88, 249]. Nevertheless, with KHINES we chose 
spontaneous GH secretion analysis as the second endocrine test as this was the only 
way to explore associations between neurosecretory dysfunction (i.e. abnormal 
spontaneous secretion in the presence of normal stimulated secretion) and PTHP 
symptoms. Although studies comparing normally growing vs poorly growing children 
but also lean vs overweight children have shown that differences in spontaneous GH 
secretion are due to lower amplitude of GH peaks rather than reduced number of GH 
secretory episodes, it is not known if TBI is associated with a similar GH secretory 
pattern or impaired GH pulsatility. 
4.4 RESULTS DISCUSSION 
4.4.1 Endocrine (growth hormone) 
Stimulated GH secretion as assessed with the ITT was abnormal in 7/25 
moderate/severe TBI participants. Although the rate of abnormal tests was in line with 
that reported in some of the earlier TBI studies that did not use confirmatory retesting, 
all KHINES participants with abnormal ITT were growing normally (lowest height SDS 
was -0.33) and were not overweight (highest BMI +1.3 SDS). IGF1 which is mainly 
regulated by GH and is a surrogate marker of GH status was within the reference 
range in all but one participant (IGF1 -2.39 SDS). IGF1 levels did not correlate with 
peak GH response to ITT even when controlling for their (normal) weight. In the study 
by Heather et al [47] that included young children with structural TBI, 8% (16/198) 
demonstrated abnormal GH responses to two stimulation tests (clonidine and arginine) 
but all 16 children had normal IGF1 levels and demonstrated normal growth at follow-




Using the overnight GH profile as the second test to assess GH status, 4/22 (using 
mean overnight GH as the diagnostic criterion) and 1/22 (using peak spontaneous GH 
secretion as the diagnostic criterion) participants would be diagnosed with GHD. IGF1 
was less than -2 SDS in two out of the four abnormal overnight profiles using mean 
overnight GH secretion as the diagnostic criterion and was also low (-2.39 SDS) in the 
single abnormal profile using peak spontaneous GH secretion as the diagnostic 
criterion. There was no correlation between peak stimulated and peak spontaneous 
GH secretion. Peak GH during sleep was generally higher compared to stimulated 
(ITT) for the same participant but the difference was not statistically significant. 
Although some studies report less than 15% discordance between stimulated and 
spontaneous GH secretion results, this does not appear to be the case with TBI 
patients as there was no concordance between the ITT and overnight GH profile result 
using either mean or peak overnight GH spontaneous secretion criteria to define a 
profile as being normal or abnormal. It would be reasonable to expect good 
concordance between these two methods of assessing GH status in clinical scenarios 
where GH secretion is severely impaired (patients with hypothalamo-pituitary 
pathology and multiple hormone deficiencies) but in TBI patients who have been 
growing normally and are asymptomatic, an abnormal result on a GH stimulation test is 
of questionable significance especially when both IGF1 and spontaneous GH secretion 
are normal. 
A possible explanation for the deceptively high rate of false positive ITT’s in TBI 
patients can be found in the design of the ITT itself. Although most ITT protocols use 
sampling at 0, 20, 30, 60, 90 and 120 min as originally described by Roth [71] these 
may not be the optimal sampling time points especially when diagnostic decisions are 
going to be based on the result of a single test. The results from deconvolution 
analysis of KHINES overnight GH profiles, but also from GH kinetic studies where GH 
and somatostatin were given in combination (somatostatin given in order to supress 
endogenous GH secretion), show that the half-life of GH is between 9-15 minutes with 
a mono-exponential disappearance curve [325]. This would suggest that in order to 
detect GH concentration peaks, GH samples should be taken at much shorter 
intervals. As peak GH levels with the ITT are achieved on average 45 min after the 
administration of insulin [326] it would be reasonable to intensify sampling around that 
time point to increase the probability of capturing the “true” peak GH response. 
KHINES TBI participants had only one stimulation test (ITT) and the high prevalence of 
GHD based on the ITT result alone without associated clinical findings, highlights the 
limitations of the ITT (more so a single ITT) to diagnose GHD in this context. As there 
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is no physiological reason for GH kinetics to change with other pharmacological stimuli 
used in stimulation tests, it is likely that the same limitations will apply if sampling 
intervals are longer than the estimated half-life of GH. 
Analysis of spontaneous GH secretion is therefore more likely to provide accurate 
information regarding not only overall GH secretion but also the pulsatile pattern of GH 
secretion which acts as a signal for tissue specific responses and can be disrupted, 
sometimes without changes in overall GH secretion. It has been shown that IGF1 
production differs in muscle and liver depending on the pattern of GH secretion [327]. 
Although basic information regarding pulsatility can be obtained by plotting GH 
concentration over time, interpretation and definition of what is a peak or pulse can be 
very subjective and does not take into account the kinetics of GH (secretion, 
distribution, elimination) which can affect the form of the GH concentration curve. It is 
therefore preferable to use pulse detection or deconvolution algorithms as described in 
detail in Section 1. Although not perfect, these almost fully automated methods enable 
direct comparisons and consistency between analyses. Analysis of KHINES participant 
GH profiles using AutoDecon demonstrated intact GH pulsatility exposing secretory 
and in contrast to the ITT, measures of spontaneous GH secretion derived from 
deconvolution correlated strongly with IGF1 levels. ApEn for GH was higher in female 
TBI participants indicating greater irregularity. This pattern reflects the physiological 
gender separation in GH secretion. ApEn was not different between participants with 
fatigue. 
For the paediatric TBI population, growth is a very sensitive indicator of somatotroph 
axis integrity and measurement of height velocity in particular has been shown to aid 
identification of TBI survivors with PTHP, providing that growth velocity remains 
consistently under the 25th centile during a follow up period or at least one year. Using 
this screening method, a third of paediatric patients will demonstrate suboptimal GH 
response to a single stimulation test with GHRH & Arginine [328].  
The prevalence of GHD in KHINES provides information about the natural history of 
PTHP after TBI in childhood. In another study with similar design (Wamstad et al. 
[329]) that enrolled slightly younger children and adolescents 3-4 years post TBI, the 
prevalence of GHD was 17% based on the overnight GH profile and 33% based on 
dynamic testing. The results of the stimulation test are almost the same (33% vs 28% 
in KHINES) using a different stimulation test (arginine/glucagon). Overnight GH 
secretion was abnormal in a smaller percentage in KHINES (5% vs 17%) using 
however more strict criteria (peak overnight GH cut-off same as the one used for the 
ITT). In the study by Wamstad the same peak overnight GH level of < 5mcg/L was 
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used to diagnose GHD even in participants that were over 18 years of age. If the same 
cut-off (5 mcg/L) was applied in KHINES, the prevalence of GHD would be 13% (3/22) 
based on the profile only and 4.5% (1/22) based on both tests (14% in the study by 
Wamstad). 
In summary and by assessing both stimulated and spontaneous GH secretion in 
moderate/severe TBI survivors the long-term prevalence of GHD is between 5-10%. 
4.4.2 Endocrine (cortisol) 
HPA axis abnormalities in KHINES were mild. In two participants stimulated cortisol 
secretion (392 and 483 nmol/l) was suboptimal using the local laboratory diagnostic 
cut-off value of 500 nmol/l. One of the participants had also suboptimal GH response to 
the ITT. In all moderate/severe TBI participants cortisol was secreted predominantly in 
the second half of the night with gradually increasing pulsatility. Salivary cortisol 
profiles did not differ between TBI participants and controls, or between participants 
with depression or fatigue. The circadian rhythm was preserved and all participants 
responded with low morning cortisol levels following suppression with oral 
dexamethasone. The two participants with suboptimal stimulated cortisol response had 
high fatigue scores. One had a bimodal score of 10 (patients with Chronic Fatigue 
Syndrome have a score of 9 or above). Although chronic stress is associated with 
chronic elevation of cortisol levels, preceded by changes of trough cortisol levels and 
loss of circadian rhythm [330, 331] this was not seen in KHINES participants. A similar 
response has been described in adult patients with depressive disorders [332]. 
Conversely, chronic pain syndromes, anxiety disorders and posttraumatic stress are 
associated with hypocortisolism [333]. 
Although changes in CAR have been described in patients with PTSD [334], chronic 
fatigue [335], hippocampal lesions [336] (blunted response) and chronically stressed, 
recovered depressed patients (enhanced response) [337], neither was seen in 
KHINES. In two participants (one healthy control and one mod/sev TBI) the CAR was 
negative over three consecutive days. The most likely explanation for these results 
would be delayed collection of the first sample after awakening or mislabelling of the 
samples. 
4.4.3 Cognitive function 
The findings of this study confirm the presence of significant cognitive impairment in 
paediatric TBI survivors 10 years following TBI as previously demonstrated in adult 
patients [338]. Anthropometric and physical function scores in our study group of TBI 
survivors suggest a good outcome from the physical disability point of view but 
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significant residual neurocognitive disability. In addition to cognitive impairment our 
study participants (mostly moderate/severe TBI) demonstrated reduced QoL, high 
rates of fatigue and depression scores. Cognitive deficits involve mainly working 
memory which are comparable to previous studies with shorter follow up post TBI 
[179]. Although significant cognitive recovery takes place during the first year after TBI, 
the rate of improvement slows down in severe TBI survivors particularly in the domains 
of performance IQ, adaptive problem solving, memory and motor skills [339]. The 
persistent deficits and lack of catch-up over time suggest the possibility of reduction in 
the rate of acquisition of new skills after severe TBI. Although TBI KHINES participants 
had total IQ scores (Full Scale Intelligence Quotient) that were not significantly different 
to that of the control group, only the moderate/severe TBI group included participants 
with IQ scores under 80. Performance IQ which is one of the last domains to recover 
was not different between groups but again only the moderate/severe TBI group 
included participants with performance IQ in the lower centiles. Verbal IQ was 
significantly lower in the moderate/severe TBI group and being linked to academic 
achievement highlights the persistent consequences and deleterious effects of TBI on 
academic performance.  
A link between the somatotropic system and cognitive function has been hypothesised 
once it was shown that GH is permeable to the brain and receptors for both GH and 
IGF1 exist in areas of the brain associated with cognitive function and behaviour [141]. 
GH treatment in adults with non-TBI related GHD has been shown to improve memory 
and attention [340] but these findings have not been reproduced in other studies [341]. 
Children with congenital hypopituitarism have an intellectual ability that is in the low-
average range compared to the population norm but not significantly different when 
compared to their siblings except for performance IQ (reflection of reduced ability to 
perform tasks requiring perceptual organisational skills) [165]. These children are 
susceptible to hypoglycaemia early in life and are also likely to have other associated 
brain malformations [166]. GH therefore appears to have a less important role in brain 
development compared to thyroid hormone. Furthermore, intelligence in children with 
GH insensitivity due to abnormal GH receptor is not different compared to controls 
indicating that GH and GH-induced IGF-1 production is not necessary for normal brain 
growth and development [167]. It is however possible that the beneficial effects of GH 
treatment in regards to cognitive function and memory are a result of neuroprotective 
properties of GH and IGF1 as demonstrated in the hippocampus [342, 343]. There is 
however agreement in that memory, attention and executive function decline in adults 




Behavioural and psychosocial problems following TBI in childhood have not received 
the same attention as the physical and cognitive consequences but many children with 
TBI demonstrate low self-esteem. This is closely linked with anxiety and depression 
and can impair academic performance leading to further psychosocial problems [345]. 
Recent studies have reported a surprisingly high incidence (31%) of novel psychiatric 
disorders in children with mild TBI in the second year post injury [346] but a systematic 
review of mild and moderate paediatric TBI studies from 2008-2013 did not show a 
clear effect [347]. Frontal white matter is particularly susceptible to injury and persistent 
changes in the area were demonstrated in KHINES participants. Executive functioning 
(task planning, inhibition, attention control, sustained effort, and mental flexibility) relies 
on frontal–striatal networks that are particularly susceptible to diffuse axonal injury 
[178]. Approximately 20 to 40% of young children (5-15 years of age) with TBI show 
significant executive dysfunction within the first year of injury [179]. In KHINES the 
prevalence of behavioural problems in the moderate/severe TBI group was significantly 
higher. This included changes in externalizing behaviour consisting of three other 
behaviour syndromes (aggressive, rule breaking and intrusive) that mainly involve 
conflicts with other people and with social mores but also problems with attention. 
Scores for internalizing behaviour consisting of three syndromes (anxious/depressed, 
withdrawal, somatic complains) were also higher in all TBI participants including those 
with mild TBI. Depression scores were significantly higher in the moderate/severe TBI 
group. 
Considering the potential neuroprotective effects of GH, studies looking at psychiatric 
outcomes in TBI patients showed a high incidence of depression, anxiety and 
psychosis, which correlated negatively with peak, stimulated GH responses. In the 
study by Wamsad et al [329], abnormal spontaneous (but not stimulated) GH secretion 
was associated with impaired visual memory and lower HRQL but this was not 
demonstrated in KHINES as there were no differences in regards to anxiety, 
depression and cognitive function between participants with normal and abnormal 
stimulated or spontaneous GH status. 
Depression has also been reported to be associated with reduced spontaneous 
(mainly nocturnal [348]) and stimulated GH secretion [349]. A similar effect was seen in 
KHINES but did not reach statistical significance, possibly due to sample size. In 
KHINES participants with depression 
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, GH pulse mass, pulse height and average GH secretion but not number of detected 
pulses was lower. It has been hypothesised that increased activity of central beta 
receptors [350] and CRH hypersecretion (which is found in patients with depression) 
exert an inhibitory effect on GH release. 
4.4.5 HRQL 
Although it is encouraging that only a small proportion of TBI survivors are left with 
significant physical disability, it is the subtle but significant issues in childhood such as 
decline in school performance (but still within the “normal” range, hence not causing 
major concerns) and behavioural changes that are often missed. To complicate things 
further, TBI survivors (much like cancer survivors) often perceive their quality of life as 
satisfactory after having to live for many years with the complications and sequelae of 
their condition. All these symptoms are difficult to capture as even detailed 
neuropsychological assessments have their limitations and can be affected by deficits 
in self-awareness (common sequelae of severe TBI) that render adolescents less 
capable of accurately rating their HRQL. Furthermore popular QoL measurement 
systems fail to consider whether the measured outcomes are relevant to the 
adolescent and capture the subtlety of the adolescent social experience [351]. 
None of KHINES TBI participants had significant physical disability as assessed with 
the PedsQL sub-score for physical functioning. Although summary and PedsQL sub-
scores (physical and psychosocial) were similar between the three KHINES groups 
(control vs mild vs moderate/severe TBI), differences emerged once comparisons were 
made between TBI and non-TBI participants. Both summary and psychosocial PedsQL 
scores (but not Physical sub-scores) were significantly lower in the TBI group. Overall, 
sixteen participants (7 mild, 9 moderate/severe TBI) had a summary PedsQL score of 
less than 69.7% (equivalent to one SD below the population mean) which has been 
shown to represent poorer HRQL. Similar results were obtained using the Health 
Utilities Index (HUI), a system of measuring health status once comparisons were 
made between TBI and non-TBI participants. Similarly to the PedsQL results, the HUI 
did not show any differences for ambulation, dexterity and pain between groups but 
attribute scores for cognition and emotion were lower in the TBI group. 
4.4.6 Fatigue 
Fatigue was one of the most prominent symptoms in KHINES TBI participants. Almost 
half (13/28) of moderate/severe TBI participants had high fatigue levels (some of them 
in the range seen only in CFS sufferers [285]) as assessed with Chalder’s fatigue 
scale. This is similar to what has been reported previously within the first two [352] or 
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five years [153] post TBI. Although not always clear unless using a standardised tool to 
measure fatigue, it is important to distinguish between physical and central fatigue. The 
former refers to impaired physical performance or exercise tolerance. This can be seen 
in TBI survivors with musculoskeletal injury and prolonged immobilisation [353]. One of 
the proposed mechanisms linking PTHP and physical fatigue is impaired muscle 
mitochondrial function secondary to GHD [354]. The latter (central fatigue) refers to the 
lack of motivation to initiate or sustain mental or physical tasks [355]. Although 
functional gains appear to continue for long periods after TBI – even after rehabilitation 
intervention has stopped – fatigue levels do not seem to follow the same pattern of 
improvement over time. This could be a result of TBI survivors realising and having to 
deal with the consequences of TBI when returning to their previous activities. 
Maintaining the same achievement level and having to “catch-up” adds an additional 
burden on TBI survivors, which over time results in increased levels of fatigue. 
Considering the high incidence of cognitive impairment in domains as executive 
functioning, memory and attention following TBI this is not unexpected [338] and is 
reflected in the employment and studying status of TBI survivors, which declines over 
time. In the study by Olver et al [153] only half of TBI survivors who were employed at 
the time of injury were employed at 2 years and even fewer after 5 years (40%). 
Although fatigue levels between GHD and non-GHD TBI survivors (irrespective of TBI 
severity) have been reported to be comparable, TBI survivors with PTHP show a 
similar benefit from GH replacement in terms of improved HRQL when compared to a 
matched group of GHD patients due to non-functioning pituitary adenoma. It is not 
known if non-GHD survivors with fatigue would respond to GH treatment in the same 
way. In a randomised, placebo controlled study evaluating the efficacy of GH therapy 
in patients with chronic fatigue and low spontaneous GH levels, Moorkens et al. 
showed there was no significant improvement in HRQL after 12 months of treatment. 
KHINES did not demonstrate any correlation between stimulated GH secretion and 
fatigue levels (even in those participants where stimulated GH response was clearly 
abnormal) and in conjunction with available evidence we cannot advocate the use of 
GH for treating fatigue symptoms in TBI survivors without solid evidence of PTHP 
using strict diagnostic criteria. 
4.5 STRENGTHS AND LIMITATIONS OF THE STUDY 
KHINES has significant strengths compared to other paediatric TBI studies. 
Recruitment was high considering that almost half of contactable KHIS participants 
agreed to take part in KHINES. KHIS, being a prospective study of outcome in children 
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with severe, moderate and mild TBI, consecutively recruited participants over a short 
period of time. This resulted in little variability in time from injury for KHINES 
participants (all between 7-11 years) and no selection bias. Clinical characteristics 
between participants and non-participants were not different (age, time from TBI, 
gender, TBI severity, socioeconomic status). 
From the endocrine perspective, all study participants had the same stimulation test 
(ITT) and overnight sampling for GH and cortisol was done in the same hospital. 
Samples were analysed at the same lab using the same assay and method for blood 
and salivary samples. All tests were done by the same researcher. 
One of the limitations of the study was not having a control group for the endocrine 
investigation arm of KHINES involving blood tests. Ethics approval was obtained for 
studying the mod/sev TBI group but not for mild TBI or controls. These groups did 
however have an assessment of their cortisol status and integrity of the HPA axis 
feedback using salivary cortisol sampling. 
Although height SDS was used for all analyses, parental adjusted height SDS would 
have been another useful outcome measure. As accurate parental heights were not 
available for most KHINES participants this was not possible. 
Spontaneous GH secretion can also show marked night to night variation (-50% to 
+100% change in night GH secretion) in the same individual [356]. Considering the 
effect of sleep on GH secretion this is probably not unexpected. Although overnight 
testing conditions were kept as much as possible the same, it is not possible to 
exclude without EEG monitoring differences in sleep quality and their effect in 
individual GH secretion.  
The final limitation to consider for this study is the number of participants that could not 
have an MRI for research purposes due to strict safety criteria (mainly metal plates 
from neurosurgery). Most of these participants had had brain surgery and were more 
likely to have suffered more severe brain damage. It is therefore possible that the 
chronic neuroimaging brain changes of TBI could be underestimated as some of the 
most severe TBI were excluded. 
4.6 FUTURE PERSPECTIVES AND POTENTIAL STUDIES 
KHINES has succeeded in its aim to determine the long term prevalence of PTHP after 
childhood TBI and has raised a number of further questions. These could be the theme 
of further studies and research papers that may include the following themes. 
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4.6.1 Methods for diagnosing PTHP 
By using strict diagnostic criteria KHINES has shown that PTHP is less frequent than 
has been previously reported. The ITT at its current implementation may not be 
suitable for diagnosing hypopituitarism in conditions where the a priori likelihood of 
pituitary disease is low as with PTHP. While the hypothesis that other GH stimulation 
tests may have similar limitations remains to be tested, we would recommend that in 
the absence of multiple hormone deficiencies and in order to facilitate prospective 
studies the diagnosis of PTHP is supported by at least two abnormal dynamic tests (or 
modified dynamic test with frequent sampling) and IGF1 levels lower than -2 SD and 
patients Link to prospective clinical scores. 
4.6.2 Identification of predictors of neuroendocrine test eligibility 
Considering the controversy of using dynamic GH endocrine tests in diagnosing PTHP 
and the practical difficulties of evaluating spontaneous GH secretion in a clinical 
setting, novel neuroimaging modalities can provide additional support in identifying TBI 
survivors that are at risk of developing PTHP. DWI has been used to indirectly assess 
the hormone secreting capacity of the pituitary in TBI patients [357] and very recently 
DTI has been successfully used to visualise the hypothalamo-hypophyseal tract 
preoperatively, reducing the risk of tract injury [358]. The same modality could 
potentially be used in TBI patients to assess the integrity of the same tract with 
prospective follow-up of clinical outcomes and to identify those most at risk of PTHP. 
4.6.3 Efficacy of GH treatment in TBI survivors with PTHP 
TBI survivors with PTHP show a similar benefit from GH replacement in terms of 
improved HRQL when compared to GHD patients due to pituitary adenomas. However, 
a randomised placebo controlled study evaluating the efficacy of GH therapy in 
patients with chronic fatigue and low spontaneous GH levels, showed no significant 
improvement in HRQL. It is not known if TBI survivors with fatigue and abnormal GH 
parameters using would respond to GH treatment in the same way. 
4.6.4 Role of GH treatment on brain repair after TBI 
There is mounting evidence about the neuroprotective effects of GH but more studies 
are necessary in order to understand the role of GH in these processes. A prospective 
randomised study comparing clinical outcomes after GH treatment in both PTHP and 
non-PTHP TBI patients would help to evaluate the contribution of GH treatment with 
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